https://trial.medpath.com/news/stgen-bio-secures-fda-cgmp-approval-for-songdo-bio-plant-komedidaskeom 2024-10-14T09:56:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stgen-bio-secures-fda-cgmp-approval-for-songdo-bio-plant-komedidaskeom 2024-10-14T09:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/iteos-awaits-non-small-cell-lung-cancer-trial-data 2024-10-14T09:10:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iteos-awaits-non-small-cell-lung-cancer-trial-data 2024-10-14T09:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-applies-for-eu-approval-of-prostate-cancer-drug-for-another-indication 2024-10-14T09:09:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-applies-for-eu-approval-of-prostate-cancer-drug-for-another-indication 2024-10-14T09:09:06+00:00 weekly 0.7 https://trial.medpath.com/news/transgene-share-price-falls-after-phase-ii-failure-marketscreener 2024-10-14T08:15:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transgene-share-price-falls-after-phase-ii-failure-marketscreener 2024-10-14T08:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-reports-positive-results-from-depemokimab-trial-research-the-market-halifax 2024-10-14T07:55:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-reports-positive-results-from-depemokimab-trial-research-the-market-halifax 2024-10-14T07:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/turnstone-biologics-announces-strategic-restructuring-to-prioritize-portfolio-and-extend 2024-10-14T07:12:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/turnstone-biologics-announces-strategic-restructuring-to-prioritize-portfolio-and-extend 2024-10-14T07:12:52+00:00 weekly 0.7 https://trial.medpath.com/news/paradigm-shift-in-rare-cancer-research-biomarker-driven-approach-reshapes-oncology-landscape 2024-10-14T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/paradigm-shift-in-rare-cancer-research-biomarker-driven-approach-reshapes-oncology-landscape 2024-10-14T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-faces-336m-waste-from-lecanemab-vial-sizes-in-alzheimer-s-treatment 2024-10-14T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicare-faces-336m-waste-from-lecanemab-vial-sizes-in-alzheimer-s-treatment 2024-10-14T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/inventiva-announces-filing-of-2024-half-year-report-conditions-for-accessing-or 2024-10-14T06:59:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inventiva-announces-filing-of-2024-half-year-report-conditions-for-accessing-or 2024-10-14T06:59:53+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-hails-phase-iii-nasal-polyps-success-proactive-investors 2024-10-14T06:54:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-hails-phase-iii-nasal-polyps-success-proactive-investors 2024-10-14T06:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-highlights-precision-medicine-approach-for-type-1-diabetes-at-the-cision-news 2024-10-14T06:46:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-highlights-precision-medicine-approach-for-type-1-diabetes-at-the-cision-news 2024-10-14T06:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/inventiva-announces-financing-of-up-to-eur348-million-to-advance-the-nativ3-phase-3-mash-study 2024-10-14T06:33:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inventiva-announces-financing-of-up-to-eur348-million-to-advance-the-nativ3-phase-3-mash-study 2024-10-14T06:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/transgene-provides-update-on-phase-ii-trial-of-therapeutic-cancer-vaccine-tg4001-in 2024-10-14T06:22:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transgene-provides-update-on-phase-ii-trial-of-therapeutic-cancer-vaccine-tg4001-in 2024-10-14T06:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-announces-positive-phase-iii-results-from-anchor-trials-for-depemokimab-in-chronic 2024-10-14T06:08:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-announces-positive-phase-iii-results-from-anchor-trials-for-depemokimab-in-chronic 2024-10-14T06:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-experts-address-cannabis-use-in-cancer-care-and-rising-drug-cost-challenges 2024-10-14T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mayo-clinic-experts-address-cannabis-use-in-cancer-care-and-rising-drug-cost-challenges 2024-10-14T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/effectiveness-and-safety-of-azvudine-versus-nirmatrelvir-ritonavir-in-adult-patients-infected 2024-10-14T05:40:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effectiveness-and-safety-of-azvudine-versus-nirmatrelvir-ritonavir-in-adult-patients-infected 2024-10-14T05:40:30+00:00 weekly 0.7 https://trial.medpath.com/news/nicox-and-soleus-sign-16-5-million-royalty-and-equity-financing 2024-10-14T05:31:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nicox-and-soleus-sign-16-5-million-royalty-and-equity-financing 2024-10-14T05:31:59+00:00 weekly 0.7 https://trial.medpath.com/news/data-driven-omnichannel-strategy-revolutionizes-healthcare-professional-engagement-in-pharma 2024-10-14T05:17:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-driven-omnichannel-strategy-revolutionizes-healthcare-professional-engagement-in-pharma 2024-10-14T05:17:32+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-receives-u-s-fda-approval-for-320-mg-single-injection-device-presentations-of 2024-10-14T05:14:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ucb-receives-u-s-fda-approval-for-320-mg-single-injection-device-presentations-of 2024-10-14T05:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/majority-of-children-with-spinal-muscular-atrophy-sma-globenewswire 2024-10-14T05:04:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/majority-of-children-with-spinal-muscular-atrophy-sma-globenewswire 2024-10-14T05:04:11+00:00 weekly 0.7 https://trial.medpath.com/news/breast-neurotization-a-breakthrough-technique-to-restore-post-mastectomy-sensation 2024-10-14T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breast-neurotization-a-breakthrough-technique-to-restore-post-mastectomy-sensation 2024-10-14T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cenyx-biotech-scores-nod-for-us-phase-1-trial-for-subarachnoid-hemorrhage-drug-kbr 2024-10-14T04:44:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cenyx-biotech-scores-nod-for-us-phase-1-trial-for-subarachnoid-hemorrhage-drug-kbr 2024-10-14T04:44:56+00:00 weekly 0.7 https://trial.medpath.com/news/ai-poised-to-transform-pharmaceutical-industry-with-208-billion-investment-by-2030 2024-10-14T04:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-poised-to-transform-pharmaceutical-industry-with-208-billion-investment-by-2030 2024-10-14T04:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-amgen-camurus-iterum-and-lexicon-biospace 2024-10-14T04:08:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-action-alert-amgen-camurus-iterum-and-lexicon-biospace 2024-10-14T04:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/5-accelerated-approvals-gone-wrong-biospace 2024-10-14T04:08:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-accelerated-approvals-gone-wrong-biospace 2024-10-14T04:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/with-myriad-recent-approvals-in-cancer-the-era-of-bispecifics-is-here-biospace 2024-10-14T04:08:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/with-myriad-recent-approvals-in-cancer-the-era-of-bispecifics-is-here-biospace 2024-10-14T04:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-endoscopic-ultrasound-guided-celiac-plexus-block-on-the-palliation-of-pain-in-trials 2024-10-14T03:30:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effect-of-endoscopic-ultrasound-guided-celiac-plexus-block-on-the-palliation-of-pain-in-trials 2024-10-14T03:30:04+00:00 weekly 0.7 https://trial.medpath.com/news/imricor-eyes-worldwide-expansion-with-progress-on-us-and-eu-regulatory-approval 2024-10-14T03:27:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imricor-eyes-worldwide-expansion-with-progress-on-us-and-eu-regulatory-approval 2024-10-14T03:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/dual-drug-combo-potential-breakthrough-for-dementia-mirage-news 2024-10-14T03:24:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dual-drug-combo-potential-breakthrough-for-dementia-mirage-news 2024-10-14T03:24:06+00:00 weekly 0.7 https://trial.medpath.com/news/24-months-clinical-prospective-of-proximal-restorations-with-repeated-preheating-bulk-fill 2024-10-14T02:54:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/24-months-clinical-prospective-of-proximal-restorations-with-repeated-preheating-bulk-fill 2024-10-14T02:54:07+00:00 weekly 0.7 https://trial.medpath.com/news/daewoong-pharmaceutical-s-diabetes-drug-wins-approval-in-ecuador-pulse 2024-10-14T02:29:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daewoong-pharmaceutical-s-diabetes-drug-wins-approval-in-ecuador-pulse 2024-10-14T02:29:36+00:00 weekly 0.7 https://trial.medpath.com/news/immuno-oncology-is-a-treatment-that-strengthens-the-immune-system-that-attacks-cancer-cells-it-effe 2024-10-14T02:29:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immuno-oncology-is-a-treatment-that-strengthens-the-immune-system-that-attacks-cancer-cells-it-effe 2024-10-14T02:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-analysis-of-haic-combined-with-lenvatinib-plus-pd1-inhibitor-vs-first-line-systemic 2024-10-14T01:54:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-analysis-of-haic-combined-with-lenvatinib-plus-pd1-inhibitor-vs-first-line-systemic 2024-10-14T01:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/privacy-friendly-evaluation-of-patient-data-with-secure-multiparty-computation-in-a-nature 2024-10-14T01:44:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/privacy-friendly-evaluation-of-patient-data-with-secure-multiparty-computation-in-a-nature 2024-10-14T01:44:06+00:00 weekly 0.7 https://trial.medpath.com/news/shanghai-s-science-ecosystem-powers-pharma-giants-innovation-shine-news 2024-10-14T01:11:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shanghai-s-science-ecosystem-powers-pharma-giants-innovation-shine-news 2024-10-14T01:11:46+00:00 weekly 0.7 https://trial.medpath.com/news/guangzhou-baiyunshan-s-generic-drug-wins-approval-tipranks-com 2024-10-14T01:10:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/guangzhou-baiyunshan-s-generic-drug-wins-approval-tipranks-com 2024-10-14T01:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-trial-stem-cells-to-cure-blindness-in-animals-bond-university 2024-10-14T01:00:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-trial-stem-cells-to-cure-blindness-in-animals-bond-university 2024-10-14T01:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/digital-technologies-transform-cognitive-assessment-in-schizophrenia-drug-trials 2024-10-14T00:52:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-technologies-transform-cognitive-assessment-in-schizophrenia-drug-trials 2024-10-14T00:52:31+00:00 weekly 0.7 https://trial.medpath.com/news/ssy-group-s-muscle-relaxant-drug-secures-china-approval-tipranks-com 2024-10-14T00:17:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ssy-group-s-muscle-relaxant-drug-secures-china-approval-tipranks-com 2024-10-14T00:17:26+00:00 weekly 0.7 https://trial.medpath.com/news/aptamer-drug-conjugates-loaded-bacteria-for-pancreatic-cancer-synergistic-therapy-nature 2024-10-14T00:08:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aptamer-drug-conjugates-loaded-bacteria-for-pancreatic-cancer-synergistic-therapy-nature 2024-10-14T00:08:08+00:00 weekly 0.7 https://trial.medpath.com/news/ux111-for-sanfilippo-syndrome-type-a-mps-iiia-ultragenyx 2024-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ux111-for-sanfilippo-syndrome-type-a-mps-iiia-ultragenyx 2024-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pacritinib-response-is-associated-with-overall-survival-in 2024-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pacritinib-response-is-associated-with-overall-survival-in 2024-10-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-pharma-shares-lift-on-clinical-trial-and-new-ceo-capital-brief 2024-10-13T23:51:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clarity-pharma-shares-lift-on-clinical-trial-and-new-ceo-capital-brief 2024-10-13T23:51:45+00:00 weekly 0.7 https://trial.medpath.com/news/effects-of-oxytocin-receptor-agonists-on-hair-growth-promotion-scientific-reports-nature 2024-10-13T23:39:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effects-of-oxytocin-receptor-agonists-on-hair-growth-promotion-scientific-reports-nature 2024-10-13T23:39:21+00:00 weekly 0.7 https://trial.medpath.com/news/new-trials-into-benefits-of-cannabis-based-medicine-for-children-with-epilepsy-belfast-live 2024-10-13T23:12:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-trials-into-benefits-of-cannabis-based-medicine-for-children-with-epilepsy-belfast-live 2024-10-13T23:12:21+00:00 weekly 0.7 https://trial.medpath.com/news/children-with-aggressive-blood-cancer-offered-treatment-cure-hope-the-independent 2024-10-13T23:10:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/children-with-aggressive-blood-cancer-offered-treatment-cure-hope-the-independent 2024-10-13T23:10:59+00:00 weekly 0.7 https://trial.medpath.com/news/boy-has-300-seizures-a-day-until-he-takes-medical-cannabis-now-there-s-hope-for-others 2024-10-13T21:32:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boy-has-300-seizures-a-day-until-he-takes-medical-cannabis-now-there-s-hope-for-others 2024-10-13T21:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/ngs-technology-advances-promise-to-transform-precision-oncology-trial-recruitment-and-diversity 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ngs-technology-advances-promise-to-transform-precision-oncology-trial-recruitment-and-diversity 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-outcome-assessments-a-critical-foundation-for-modern-drug-development-success 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-outcome-assessments-a-critical-foundation-for-modern-drug-development-success 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/strategic-hub-partner-selection-critical-for-successful-drug-launch-and-patient-support 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strategic-hub-partner-selection-critical-for-successful-drug-launch-and-patient-support 2024-10-13T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tvtx-investor-alert-bronstein-gewirtz-and-grossman-llc-globenewswire 2024-10-13T20:21:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tvtx-investor-alert-bronstein-gewirtz-and-grossman-llc-globenewswire 2024-10-13T20:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/blinklab-asx-bb1-is-this-exciting-company-the-next-resapp-stocks-down-under 2024-10-13T19:21:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blinklab-asx-bb1-is-this-exciting-company-the-next-resapp-stocks-down-under 2024-10-13T19:21:53+00:00 weekly 0.7 https://trial.medpath.com/news/her2-positive-treatment-resistant-breast-cancer-treatment-breakthrough-hmri 2024-10-13T17:39:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/her2-positive-treatment-resistant-breast-cancer-treatment-breakthrough-hmri 2024-10-13T17:39:15+00:00 weekly 0.7 https://trial.medpath.com/news/miles-matter-the-geographic-disparity-that-impacts-access-to-car-t-therapy 2024-10-13T16:52:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/miles-matter-the-geographic-disparity-that-impacts-access-to-car-t-therapy 2024-10-13T16:52:50+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-breakthrough-new-miracle-treatment-yields-remarkable-results-this-could-be-the-cure 2024-10-13T16:30:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-breakthrough-new-miracle-treatment-yields-remarkable-results-this-could-be-the-cure 2024-10-13T16:30:33+00:00 weekly 0.7 https://trial.medpath.com/news/startups-are-biohacking-psychedelic-drugs-to-make-sure-you-never-have-a-bad-trip-again 2024-10-13T16:08:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/startups-are-biohacking-psychedelic-drugs-to-make-sure-you-never-have-a-bad-trip-again 2024-10-13T16:08:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-gets-drugs-out-faster-but-some-work-only-marginally-better-and-are-more-expensive 2024-10-13T14:30:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-gets-drugs-out-faster-but-some-work-only-marginally-better-and-are-more-expensive 2024-10-13T14:30:32+00:00 weekly 0.7 https://trial.medpath.com/news/prostate-cancer-holy-grail-spit-test-could-save-nhs-ps500m-every-year-express-co-uk 2024-10-13T14:24:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prostate-cancer-holy-grail-spit-test-could-save-nhs-ps500m-every-year-express-co-uk 2024-10-13T14:24:21+00:00 weekly 0.7 https://trial.medpath.com/news/internet-based-cognitive-behavioral-intervention-for-adolescents-with-anxiety-disorders-trials 2024-10-13T13:57:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/internet-based-cognitive-behavioral-intervention-for-adolescents-with-anxiety-disorders-trials 2024-10-13T13:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/point-of-care-hepatitis-c-test-may-expedite-diagnosis-contagion-live 2024-10-13T13:35:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/point-of-care-hepatitis-c-test-may-expedite-diagnosis-contagion-live 2024-10-13T13:35:58+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-secures-250-million-usd-to-propel-global-expansion-of-its-innovative-drug-pipeline 2024-10-13T13:22:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/akeso-secures-250-million-usd-to-propel-global-expansion-of-its-innovative-drug-pipeline 2024-10-13T13:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/gammora-breakthrough-hiv-treatment-to-be-presented-at-international-conferences 2024-10-13T13:17:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gammora-breakthrough-hiv-treatment-to-be-presented-at-international-conferences 2024-10-13T13:17:17+00:00 weekly 0.7 https://trial.medpath.com/news/junshi-biosciences-ongericimab-wins-drug-approval-tipranks-com 2024-10-13T11:07:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/junshi-biosciences-ongericimab-wins-drug-approval-tipranks-com 2024-10-13T11:07:54+00:00 weekly 0.7 https://trial.medpath.com/news/the-targeted-pulse-uncover-essential-developments-in-breast-cancer-multiple-myeloma 2024-10-13T11:04:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-targeted-pulse-uncover-essential-developments-in-breast-cancer-multiple-myeloma 2024-10-13T11:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/nanoscope-therapeutics-inc-acquires-a-license-for-the-catch-technology-modern-retina 2024-10-13T10:16:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoscope-therapeutics-inc-acquires-a-license-for-the-catch-technology-modern-retina 2024-10-13T10:16:17+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-high-prevalence-of-fibromyalgia-in-post-covid-musculoskeletal-pain-patients 2024-10-13T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-high-prevalence-of-fibromyalgia-in-post-covid-musculoskeletal-pain-patients 2024-10-13T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sunvozertinib-granted-breakthrough-therapy-designation-by-china-cde-for-the-first-line 2024-10-13T08:08:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sunvozertinib-granted-breakthrough-therapy-designation-by-china-cde-for-the-first-line 2024-10-13T08:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/ftc-takes-legal-action-against-top-pbms-over-insulin-pricing-practices 2024-10-13T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ftc-takes-legal-action-against-top-pbms-over-insulin-pricing-practices 2024-10-13T06:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/data-presented-from-the-phase-1b-clinical-trial-evaluating-low-dose-lti-03-in-idiopathic-pulmonary-fibrosis 2024-10-13T04:10:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-presented-from-the-phase-1b-clinical-trial-evaluating-low-dose-lti-03-in-idiopathic-pulmonary-fibrosis 2024-10-13T04:10:21+00:00 weekly 0.7 https://trial.medpath.com/news/secukinumab-adalimumab-have-distinct-advantages-for-treating-psa-hcplive 2024-10-13T03:04:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/secukinumab-adalimumab-have-distinct-advantages-for-treating-psa-hcplive 2024-10-13T03:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/exact-sciences-launches-cologuard-plus-for-enhanced-colorectal-cancer-screening-in-adults-45-and-older 2024-10-13T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exact-sciences-launches-cologuard-plus-for-enhanced-colorectal-cancer-screening-in-adults-45-and-older 2024-10-13T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-regimen-could-improve-outcomes-in-transplantation-from-half-matched-donors 2024-10-13T01:36:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-regimen-could-improve-outcomes-in-transplantation-from-half-matched-donors 2024-10-13T01:36:54+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-that-means-most-lethal-cancer-is-a-death-sentence-no-more-how-miracle-drug 2024-10-13T01:27:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-that-means-most-lethal-cancer-is-a-death-sentence-no-more-how-miracle-drug 2024-10-13T01:27:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-indication-for-navidea-s-lymphatic-mapping-agent-rttnews 2024-10-12T22:36:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-indication-for-navidea-s-lymphatic-mapping-agent-rttnews 2024-10-12T22:36:48+00:00 weekly 0.7 https://trial.medpath.com/news/iv-secukinumab-rapidly-improved-clinical-responses-in-psoriatic-arthritis-hcplive 2024-10-12T21:01:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iv-secukinumab-rapidly-improved-clinical-responses-in-psoriatic-arthritis-hcplive 2024-10-12T21:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-to-reconsider-decision-barring-compounded-versions-of-lilly-weight-loss-drug 2024-10-12T20:18:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-to-reconsider-decision-barring-compounded-versions-of-lilly-weight-loss-drug 2024-10-12T20:18:51+00:00 weekly 0.7 https://trial.medpath.com/news/scientific-advisory-committee-on-health-products-for-women-sac-hpw-canada-ca 2024-10-12T19:51:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scientific-advisory-committee-on-health-products-for-women-sac-hpw-canada-ca 2024-10-12T19:51:05+00:00 weekly 0.7 https://trial.medpath.com/news/2-biotech-stocks-that-are-screaming-buys-this-month 2024-10-12T17:59:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2-biotech-stocks-that-are-screaming-buys-this-month 2024-10-12T17:59:57+00:00 weekly 0.7 https://trial.medpath.com/news/race-based-correction-in-pulmonary-function-testing-in-copd-research 2024-10-12T17:42:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/race-based-correction-in-pulmonary-function-testing-in-copd-research 2024-10-12T17:42:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-says-medtronic-can-study-affera-pulsed-field-ablation-system-for-treating-ventricular-tachycardia 2024-10-12T17:40:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-says-medtronic-can-study-affera-pulsed-field-ablation-system-for-treating-ventricular-tachycardia 2024-10-12T17:40:31+00:00 weekly 0.7 https://trial.medpath.com/news/why-were-so-few-randomized-trials-of-public-health-and-social-measures-conducted-during 2024-10-12T16:33:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-were-so-few-randomized-trials-of-public-health-and-social-measures-conducted-during 2024-10-12T16:33:21+00:00 weekly 0.7 https://trial.medpath.com/news/benitec-biopharma-reports-positive-data-from-two-subjects-globenewswire 2024-10-12T16:31:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/benitec-biopharma-reports-positive-data-from-two-subjects-globenewswire 2024-10-12T16:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/7-year-old-paxton-in-remission-after-participating-in-new-cancer-drug-trial-at-ascension 2024-10-12T16:26:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/7-year-old-paxton-in-remission-after-participating-in-new-cancer-drug-trial-at-ascension 2024-10-12T16:26:49+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-new-pill-cuts-alcohol-consumption-by-over-50-the-brighter-side-of-news 2024-10-12T16:23:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-new-pill-cuts-alcohol-consumption-by-over-50-the-brighter-side-of-news 2024-10-12T16:23:41+00:00 weekly 0.7 https://trial.medpath.com/news/thyme-care-appoints-value-based-care-expert-dr-lalan-wilfong-to-lead-oncology-transformation 2024-10-12T14:35:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thyme-care-appoints-value-based-care-expert-dr-lalan-wilfong-to-lead-oncology-transformation 2024-10-12T14:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/thyme-care-secures-95m-series-c-funding-to-transform-value-based-cancer-care-delivery 2024-10-12T13:54:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thyme-care-secures-95m-series-c-funding-to-transform-value-based-cancer-care-delivery 2024-10-12T13:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/neural-network-models-help-predict-immunotherapy-efficacy-in-small-cell-lung-cancer 2024-10-12T13:50:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neural-network-models-help-predict-immunotherapy-efficacy-in-small-cell-lung-cancer 2024-10-12T13:50:13+00:00 weekly 0.7 https://trial.medpath.com/news/corin-receives-fda-510-k-clearance-of-medial-constrained-tibial-insert-for-tka-healio 2024-10-12T13:37:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corin-receives-fda-510-k-clearance-of-medial-constrained-tibial-insert-for-tka-healio 2024-10-12T13:37:54+00:00 weekly 0.7 https://trial.medpath.com/news/remote-ischemic-post-conditioning-for-neonatal-encephalopathy-a-safety-and-feasibility-trial 2024-10-12T13:27:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/remote-ischemic-post-conditioning-for-neonatal-encephalopathy-a-safety-and-feasibility-trial 2024-10-12T13:27:01+00:00 weekly 0.7 https://trial.medpath.com/news/aileron-therapeutics-to-present-previously-announced-data-from-the-phase-1b-clinical-trial 2024-10-12T13:09:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aileron-therapeutics-to-present-previously-announced-data-from-the-phase-1b-clinical-trial 2024-10-12T13:09:34+00:00 weekly 0.7 https://trial.medpath.com/news/cgrp-monoclonal-antibodies-not-more-effective-than-topiramate-or-botox-for-treating-migraine 2024-10-12T12:58:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgrp-monoclonal-antibodies-not-more-effective-than-topiramate-or-botox-for-treating-migraine 2024-10-12T12:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/study-identifies-genetic-factors-crucial-in-acute-myeloid-leukemia-survival-for-black-patients 2024-10-12T12:14:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-identifies-genetic-factors-crucial-in-acute-myeloid-leukemia-survival-for-black-patients 2024-10-12T12:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/fixed-duration-ibrutinib-venetoclax-elicits-meaningful-survival-benefit-in-high-risk-cll-sll 2024-10-12T11:24:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fixed-duration-ibrutinib-venetoclax-elicits-meaningful-survival-benefit-in-high-risk-cll-sll 2024-10-12T11:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/home-blood-pressure-lowering-effect-of-esaxerenone-versus-trichlormethiazide-for-nature 2024-10-12T10:13:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/home-blood-pressure-lowering-effect-of-esaxerenone-versus-trichlormethiazide-for-nature 2024-10-12T10:13:22+00:00 weekly 0.7 https://trial.medpath.com/news/market-today-cvs-exits-infusion-services-tesla-s-robot-controv-gurufocus 2024-10-12T10:03:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/market-today-cvs-exits-infusion-services-tesla-s-robot-controv-gurufocus 2024-10-12T10:03:21+00:00 weekly 0.7 https://trial.medpath.com/news/topiramate-pregabalin-reduce-headache-frequency-intensity-in-pediatric-migraine 2024-10-12T08:03:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/topiramate-pregabalin-reduce-headache-frequency-intensity-in-pediatric-migraine 2024-10-12T08:03:04+00:00 weekly 0.7 https://trial.medpath.com/news/the-origins-of-modern-surgery-radical-mastectomy-and-the-first-randomized-trials-in-breast-cancer 2024-10-12T07:38:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-origins-of-modern-surgery-radical-mastectomy-and-the-first-randomized-trials-in-breast-cancer 2024-10-12T07:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/tirbanibulin-demonstrates-efficacy-for-actinic-keratosis-in-larger-field-treatment 2024-10-12T07:15:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirbanibulin-demonstrates-efficacy-for-actinic-keratosis-in-larger-field-treatment 2024-10-12T07:15:14+00:00 weekly 0.7 https://trial.medpath.com/news/hopa-president-highlights-evolution-and-challenges-for-women-in-pharmacy-leadership 2024-10-12T07:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hopa-president-highlights-evolution-and-challenges-for-women-in-pharmacy-leadership 2024-10-12T07:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/cisplatin-s-prevalence-in-bladder-cancer-falters-with-the-introduction-of-enfortumab-vedotin 2024-10-12T07:03:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cisplatin-s-prevalence-in-bladder-cancer-falters-with-the-introduction-of-enfortumab-vedotin 2024-10-12T07:03:56+00:00 weekly 0.7 https://trial.medpath.com/news/engineered-hsv-can-trigger-genetic-chain-reaction-rejigger-hsv-genes-during-co-infection 2024-10-12T04:32:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/engineered-hsv-can-trigger-genetic-chain-reaction-rejigger-hsv-genes-during-co-infection 2024-10-12T04:32:34+00:00 weekly 0.7 https://trial.medpath.com/news/biomarker-testing-critical-for-optimizing-early-stage-nsclc-treatment-decisions 2024-10-12T04:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomarker-testing-critical-for-optimizing-early-stage-nsclc-treatment-decisions 2024-10-12T04:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/sareum-holdings-completes-gbp2-4-million-fundraise-to-boost-lead-asset 2024-10-12T03:09:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sareum-holdings-completes-gbp2-4-million-fundraise-to-boost-lead-asset 2024-10-12T03:09:04+00:00 weekly 0.7 https://trial.medpath.com/news/new-therapeutic-strategy-offers-hope-for-treating-aggressive-triple-negative-breast-cancer 2024-10-12T02:24:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-therapeutic-strategy-offers-hope-for-treating-aggressive-triple-negative-breast-cancer 2024-10-12T02:24:01+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-personalization-is-poised-to-define-new-era-of-mcrc-therapy-onclive 2024-10-12T02:22:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/treatment-personalization-is-poised-to-define-new-era-of-mcrc-therapy-onclive 2024-10-12T02:22:46+00:00 weekly 0.7 https://trial.medpath.com/news/upstream-raises-255m-ipo-for-inflammatory-drugs-camp4-nets-75m-for-rna-work 2024-10-12T02:21:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/upstream-raises-255m-ipo-for-inflammatory-drugs-camp4-nets-75m-for-rna-work 2024-10-12T02:21:44+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-drug-could-be-used-to-save-the-limbs-of-peripheral-artery-disease-patients-pre 2024-10-12T01:39:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-drug-could-be-used-to-save-the-limbs-of-peripheral-artery-disease-patients-pre 2024-10-12T01:39:51+00:00 weekly 0.7 https://trial.medpath.com/news/obesity-trial-surge-puts-the-focus-back-on-decentralisation-clinical-trials-arena 2024-10-12T01:33:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obesity-trial-surge-puts-the-focus-back-on-decentralisation-clinical-trials-arena 2024-10-12T01:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/mace-in-cv-trials-has-the-outcome-outlived-its-role-tctmd-com 2024-10-11T22:57:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mace-in-cv-trials-has-the-outcome-outlived-its-role-tctmd-com 2024-10-11T22:57:53+00:00 weekly 0.7 https://trial.medpath.com/news/nurix-therapeutics-reports-third-quarter-fiscal-2024-financial-results-and-provides-a 2024-10-11T22:37:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurix-therapeutics-reports-third-quarter-fiscal-2024-financial-results-and-provides-a 2024-10-11T22:37:21+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-extends-partnership-with-keybioscience-pharmaceutical-executive 2024-10-11T22:03:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lilly-extends-partnership-with-keybioscience-pharmaceutical-executive 2024-10-11T22:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/dr-wolf-on-challenges-conducting-clinical-trials-evaluating-surgery-in-mesothelioma 2024-10-11T21:08:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-wolf-on-challenges-conducting-clinical-trials-evaluating-surgery-in-mesothelioma 2024-10-11T21:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/tezepelumab-for-severe-asthma-improves-the-odds-of-a-good-night-s-sleep-medpage-today 2024-10-11T21:02:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tezepelumab-for-severe-asthma-improves-the-odds-of-a-good-night-s-sleep-medpage-today 2024-10-11T21:02:20+00:00 weekly 0.7 https://trial.medpath.com/news/innocan-pharma-s-lpt-cbd-shows-long-term-success-in-relieving-osteoarthritis-pain-in-dogs 2024-10-11T20:59:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innocan-pharma-s-lpt-cbd-shows-long-term-success-in-relieving-osteoarthritis-pain-in-dogs 2024-10-11T20:59:47+00:00 weekly 0.7 https://trial.medpath.com/news/bellaseno-s-clinical-trial-on-3d-printed-breast-implants-shows-promising-early-results 2024-10-11T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bellaseno-s-clinical-trial-on-3d-printed-breast-implants-shows-promising-early-results 2024-10-11T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-discontinues-denali-partnered-ms-trial-after-phase-2-failure-endpoints-news 2024-10-11T20:42:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-discontinues-denali-partnered-ms-trial-after-phase-2-failure-endpoints-news 2024-10-11T20:42:49+00:00 weekly 0.7 https://trial.medpath.com/news/safety-data-favor-diuretic-strategy-triggered-by-cardiac-monitoring-alerts-in-hf 2024-10-11T20:26:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safety-data-favor-diuretic-strategy-triggered-by-cardiac-monitoring-alerts-in-hf 2024-10-11T20:26:49+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-at-fda-new-dscsa-exemptions-hemophilia-prophylactic-approved-and-more 2024-10-11T20:22:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/this-week-at-fda-new-dscsa-exemptions-hemophilia-prophylactic-approved-and-more 2024-10-11T20:22:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-single-dose-intravenous-paclitaxel-biosimilar-for-breast-cancer-onclive 2024-10-11T20:18:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-single-dose-intravenous-paclitaxel-biosimilar-for-breast-cancer-onclive 2024-10-11T20:18:06+00:00 weekly 0.7 https://trial.medpath.com/news/pa-psychedelic-bulletin-176-drug-developers-discuss-trial-design-massachusetts-vote 2024-10-11T20:01:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pa-psychedelic-bulletin-176-drug-developers-discuss-trial-design-massachusetts-vote 2024-10-11T20:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/norstella-introduces-a-fully-integrated-data-asset-for-biopharma 2024-10-11T19:07:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/norstella-introduces-a-fully-integrated-data-asset-for-biopharma 2024-10-11T19:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/genentech-secures-fda-approval-for-inavolisib-in-advanced-hr-her2-breast-cancer 2024-10-11T19:06:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genentech-secures-fda-approval-for-inavolisib-in-advanced-hr-her2-breast-cancer 2024-10-11T19:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/otc-markets-hosts-virtual-investor-presentation-with-christian-kanstrup-ceo-of-evaxion 2024-10-11T18:58:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/otc-markets-hosts-virtual-investor-presentation-with-christian-kanstrup-ceo-of-evaxion 2024-10-11T18:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-lmp744-for-glioma-onclive 2024-10-11T18:45:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-lmp744-for-glioma-onclive 2024-10-11T18:45:18+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-trials-begin-in-newcastle-for-pancreatic-cancer-patients-nbn-news 2024-10-11T18:36:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-clinical-trials-begin-in-newcastle-for-pancreatic-cancer-patients-nbn-news 2024-10-11T18:36:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-sees-no-need-for-dccr-advisory-committee-meeting-prader-willi-syndrome-news 2024-10-11T18:04:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-sees-no-need-for-dccr-advisory-committee-meeting-prader-willi-syndrome-news 2024-10-11T18:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/uzedy-reducing-the-risk-of-relapse-in-patients-with-schizophrenia-psychiatric-times 2024-10-11T18:03:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uzedy-reducing-the-risk-of-relapse-in-patients-with-schizophrenia-psychiatric-times 2024-10-11T18:03:24+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-finds-multidisciplinary-approach-improves-quality-of-life-for-movement-disorder-patients 2024-10-11T17:55:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-finds-multidisciplinary-approach-improves-quality-of-life-for-movement-disorder-patients 2024-10-11T17:55:24+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-guidelines-for-mpn-reflect-new-drugs-focus-on-clinical-trials 2024-10-11T17:53:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nccn-guidelines-for-mpn-reflect-new-drugs-focus-on-clinical-trials 2024-10-11T17:53:35+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-s-new-hemophilia-drug-hympavzi-gains-fda-approval-investing-com 2024-10-11T17:50:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-s-new-hemophilia-drug-hympavzi-gains-fda-approval-investing-com 2024-10-11T17:50:33+00:00 weekly 0.7 https://trial.medpath.com/news/acticor-biotech-repositions-glenzocimab-in-the-treatment-of-myocardial-infarction 2024-10-11T17:38:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acticor-biotech-repositions-glenzocimab-in-the-treatment-of-myocardial-infarction 2024-10-11T17:38:41+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-approves-foundationone-r-liquid-cdx-as-a-companion 2024-10-11T16:39:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-food-and-drug-administration-approves-foundationone-r-liquid-cdx-as-a-companion 2024-10-11T16:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/sublingual-epinephrine-film-moving-forward-nda-anticipated-by-early-next-year-healio 2024-10-11T16:22:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sublingual-epinephrine-film-moving-forward-nda-anticipated-by-early-next-year-healio 2024-10-11T16:22:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-elinzanetant-nda-for-menopause-symptoms-and-other-health-updates 2024-10-11T16:15:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-elinzanetant-nda-for-menopause-symptoms-and-other-health-updates 2024-10-11T16:15:17+00:00 weekly 0.7 https://trial.medpath.com/news/popliteal-plexus-block-compared-with-tibial-nerve-block-on-rehabilitation-goals-following-total 2024-10-11T16:15:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/popliteal-plexus-block-compared-with-tibial-nerve-block-on-rehabilitation-goals-following-total 2024-10-11T16:15:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-roche-breast-cancer-drug-turnstone-lays-off-60-of-staff-biopharma-dive 2024-10-11T16:13:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-roche-breast-cancer-drug-turnstone-lays-off-60-of-staff-biopharma-dive 2024-10-11T16:13:33+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-drugs-like-ozempic-may-protect-brain-health-several-studies-show 2024-10-11T16:11:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-drugs-like-ozempic-may-protect-brain-health-several-studies-show 2024-10-11T16:11:37+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-breakthrough-study-unveils-new-culprits-that-could-revolutionize-treatment-approaches 2024-10-11T15:56:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzheimer-s-breakthrough-study-unveils-new-culprits-that-could-revolutionize-treatment-approaches 2024-10-11T15:56:11+00:00 weekly 0.7 https://trial.medpath.com/news/mirum-pharmaceuticals-volixibat-garners-buy-rating-amidst-breakthrough-therapy 2024-10-11T15:51:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mirum-pharmaceuticals-volixibat-garners-buy-rating-amidst-breakthrough-therapy 2024-10-11T15:51:15+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-obesity-drug-on-track-for-japan-approval-next-year-ceo-nikkei-asia 2024-10-11T15:25:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-obesity-drug-on-track-for-japan-approval-next-year-ceo-nikkei-asia 2024-10-11T15:25:32+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-expects-pneumonia-drug-approval-in-india-soon-cnbc-tv18 2024-10-11T15:22:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wockhardt-expects-pneumonia-drug-approval-in-india-soon-cnbc-tv18 2024-10-11T15:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/an-antigen-discovery-pipeline-integrates-multi-omics-data-and-informs-immunotherapy 2024-10-11T15:18:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-antigen-discovery-pipeline-integrates-multi-omics-data-and-informs-immunotherapy 2024-10-11T15:18:59+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-gets-favourable-recommendation-from-cdsco-for-antibiotic-for-cabp 2024-10-11T15:10:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wockhardt-gets-favourable-recommendation-from-cdsco-for-antibiotic-for-cabp 2024-10-11T15:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/hope-for-new-test-treatment-for-endometriosis 2024-10-11T15:10:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-for-new-test-treatment-for-endometriosis 2024-10-11T15:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/disruption-of-asxl1-gene-improves-tumor-control-in-immunotherapy 2024-10-11T15:08:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disruption-of-asxl1-gene-improves-tumor-control-in-immunotherapy 2024-10-11T15:08:48+00:00 weekly 0.7 https://trial.medpath.com/news/sintilimab-bevacizumab-in-relapsed-or-persistent-ovarian-clear-cell-carcinoma 2024-10-11T15:00:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sintilimab-bevacizumab-in-relapsed-or-persistent-ovarian-clear-cell-carcinoma 2024-10-11T15:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/tempest-therapeutics-shares-retain-buy-rating-post-roche-deal-investing-com 2024-10-11T14:57:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tempest-therapeutics-shares-retain-buy-rating-post-roche-deal-investing-com 2024-10-11T14:57:41+00:00 weekly 0.7 https://trial.medpath.com/news/admi-applauds-india-s-decision-to-maintain-stringent-clinical-trial-requirements-for-ivds 2024-10-11T14:29:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/admi-applauds-india-s-decision-to-maintain-stringent-clinical-trial-requirements-for-ivds 2024-10-11T14:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/graded-oral-challenge-safe-effective-for-pediatric-macrolide-allergy-hcplive 2024-10-11T14:03:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/graded-oral-challenge-safe-effective-for-pediatric-macrolide-allergy-hcplive 2024-10-11T14:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/aha-advocates-for-expanded-lipoprotein-apheresis-use-in-high-risk-cardiovascular-patients 2024-10-11T14:00:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aha-advocates-for-expanded-lipoprotein-apheresis-use-in-high-risk-cardiovascular-patients 2024-10-11T14:00:03+00:00 weekly 0.7 https://trial.medpath.com/news/viltepso-r-viltolarsen-injection-phase-ii-study-galactic53-trial-data-published-in 2024-10-11T13:56:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viltepso-r-viltolarsen-injection-phase-ii-study-galactic53-trial-data-published-in 2024-10-11T13:56:21+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-denali-abandon-mid-stage-multiple-sclerosis-study-on-disappointing-data 2024-10-11T13:32:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-denali-abandon-mid-stage-multiple-sclerosis-study-on-disappointing-data 2024-10-11T13:32:29+00:00 weekly 0.7 https://trial.medpath.com/news/acrivon-therapeutics-announces-initial-patient-dosing-in-globenewswire 2024-10-11T13:20:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acrivon-therapeutics-announces-initial-patient-dosing-in-globenewswire 2024-10-11T13:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/expert-outlines-key-factors-in-selecting-car-t-cell-therapies-for-follicular-lymphoma 2024-10-11T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-outlines-key-factors-in-selecting-car-t-cell-therapies-for-follicular-lymphoma 2024-10-11T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-biosciences-announces-late-breaking-oral-presentation-on-preliminary-safety-and 2024-10-11T12:50:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tyra-biosciences-announces-late-breaking-oral-presentation-on-preliminary-safety-and 2024-10-11T12:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/harm-effects-in-non-registered-versus-registered-randomized-controlled-trials-of-medications 2024-10-11T12:32:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/harm-effects-in-non-registered-versus-registered-randomized-controlled-trials-of-medications 2024-10-11T12:32:24+00:00 weekly 0.7 https://trial.medpath.com/news/patient-advocate-led-study-reveals-need-for-dosing-reform-in-metastatic-breast-cancer 2024-10-11T12:24:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-advocate-led-study-reveals-need-for-dosing-reform-in-metastatic-breast-cancer 2024-10-11T12:24:40+00:00 weekly 0.7 https://trial.medpath.com/news/cantargia-reports-new-positive-results-on-biomarkers-and-safety-in-can10-phase-1-clinical-study 2024-10-11T10:15:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cantargia-reports-new-positive-results-on-biomarkers-and-safety-in-can10-phase-1-clinical-study 2024-10-11T10:15:13+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-validation-of-a-tissue-agnostic-genome-wide-methylome-enrichment-molecular-pubmed 2024-10-11T09:21:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-validation-of-a-tissue-agnostic-genome-wide-methylome-enrichment-molecular-pubmed 2024-10-11T09:21:50+00:00 weekly 0.7 https://trial.medpath.com/news/clario-partners-with-pathai-to-enhance-efficiency-in-gi-clinical-trials-yahoo 2024-10-11T09:21:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clario-partners-with-pathai-to-enhance-efficiency-in-gi-clinical-trials-yahoo 2024-10-11T09:21:50+00:00 weekly 0.7 https://trial.medpath.com/news/hivr4p-2024-research-highlights-reproductive-health-while-on-prep-and-signals-to-hiv-gov 2024-10-11T08:59:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hivr4p-2024-research-highlights-reproductive-health-while-on-prep-and-signals-to-hiv-gov 2024-10-11T08:59:48+00:00 weekly 0.7 https://trial.medpath.com/news/lixisenatide-shows-promise-in-early-parkinson-s-disease-treatment-trial 2024-10-11T07:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lixisenatide-shows-promise-in-early-parkinson-s-disease-treatment-trial 2024-10-11T07:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/sclc-staging-determines-treatment-adverse-events-oncology-nursing-news 2024-10-11T07:04:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sclc-staging-determines-treatment-adverse-events-oncology-nursing-news 2024-10-11T07:04:29+00:00 weekly 0.7 https://trial.medpath.com/news/clonal-evolution-study-reveals-treatment-patterns-in-lower-risk-mds-patients 2024-10-11T06:55:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clonal-evolution-study-reveals-treatment-patterns-in-lower-risk-mds-patients 2024-10-11T06:55:49+00:00 weekly 0.7 https://trial.medpath.com/news/nih-names-3-hubs-for-primary-care-clinical-research-network-healthcare-innovation 2024-10-11T05:08:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-names-3-hubs-for-primary-care-clinical-research-network-healthcare-innovation 2024-10-11T05:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/ruanjian-qingmai-granules-for-the-treatment-of-early-symptomatic-peri-ijgm 2024-10-11T05:03:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ruanjian-qingmai-granules-for-the-treatment-of-early-symptomatic-peri-ijgm 2024-10-11T05:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/experts-debate-optimal-sequencing-of-adcs-in-her2-low-metastatic-breast-cancer-treatment 2024-10-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-debate-optimal-sequencing-of-adcs-in-her2-low-metastatic-breast-cancer-treatment 2024-10-11T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nmpa-grants-marketing-approval-to-the-first-co-developed-ngs-based-companion 2024-10-11T04:49:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nmpa-grants-marketing-approval-to-the-first-co-developed-ngs-based-companion 2024-10-11T04:49:30+00:00 weekly 0.7 https://trial.medpath.com/news/eu-authority-mulls-paying-for-late-stage-research-as-a-pull-incentive-for-neglected-pink-sheet 2024-10-11T04:30:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-authority-mulls-paying-for-late-stage-research-as-a-pull-incentive-for-neglected-pink-sheet 2024-10-11T04:30:09+00:00 weekly 0.7 https://trial.medpath.com/news/adaptive-deep-brain-stimulation-trial-results-poised-to-transform-parkinson-s-disease 2024-10-11T04:24:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adaptive-deep-brain-stimulation-trial-results-poised-to-transform-parkinson-s-disease 2024-10-11T04:24:10+00:00 weekly 0.7 https://trial.medpath.com/news/specialty-pharmacies-and-ambulatory-infusion-centers-drive-healthcare-cost-savings-and-enhanced-patient-experience 2024-10-11T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/specialty-pharmacies-and-ambulatory-infusion-centers-drive-healthcare-cost-savings-and-enhanced-patient-experience 2024-10-11T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-enters-talks-with-cd-r-for-16-4b-consumer-health-unit-sale 2024-10-11T03:47:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-enters-talks-with-cd-r-for-16-4b-consumer-health-unit-sale 2024-10-11T03:47:00+00:00 weekly 0.7 https://trial.medpath.com/news/gritstone-files-for-bankruptcy-in-effort-to-save-clinical-research-biospace 2024-10-11T03:29:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gritstone-files-for-bankruptcy-in-effort-to-save-clinical-research-biospace 2024-10-11T03:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/hussman-institute-alzheimer-s-experts-lead-apoe4-research-at-nih-meeting-inventum 2024-10-11T03:01:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hussman-institute-alzheimer-s-experts-lead-apoe4-research-at-nih-meeting-inventum 2024-10-11T03:01:05+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-new-drug-suppresses-systemic-inflammatory-response-syndrome-resulting-from 2024-10-11T02:29:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-shows-new-drug-suppresses-systemic-inflammatory-response-syndrome-resulting-from 2024-10-11T02:29:44+00:00 weekly 0.7 https://trial.medpath.com/news/booster-therapeutics-launches-with-15m-to-develop-novel-proteasome-activator-platform-for-neurodegenerative-diseases 2024-10-11T02:12:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/booster-therapeutics-launches-with-15m-to-develop-novel-proteasome-activator-platform-for-neurodegenerative-diseases 2024-10-11T02:12:26+00:00 weekly 0.7 https://trial.medpath.com/news/molecularly-targeted-therapeutics-are-precisely-aimed-onclive 2024-10-11T02:08:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/molecularly-targeted-therapeutics-are-precisely-aimed-onclive 2024-10-11T02:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/vanqua-s-parkinson-s-drug-shows-promise-as-company-initiates-phase-ib-study 2024-10-11T01:49:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vanqua-s-parkinson-s-drug-shows-promise-as-company-initiates-phase-ib-study 2024-10-11T01:49:11+00:00 weekly 0.7 https://trial.medpath.com/news/dong-a-st-s-stelara-biosimilar-imuldosa-scores-fda-approval-pharma-article-kbr 2024-10-11T01:44:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dong-a-st-s-stelara-biosimilar-imuldosa-scores-fda-approval-pharma-article-kbr 2024-10-11T01:44:30+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-drug-breakthrough-boosts-heart-patient-hopes-mirage-news 2024-10-10T23:21:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-drug-breakthrough-boosts-heart-patient-hopes-mirage-news 2024-10-10T23:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/high-concentration-mabs-present-manufacturing-challenges-as-demand-surges-reports-cphi-europe 2024-10-10T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-concentration-mabs-present-manufacturing-challenges-as-demand-surges-reports-cphi-europe 2024-10-10T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bofa-securities-reiterates-buy-rating-on-alnylam-stock-highlights-amvuttra-launch-strategy 2024-10-10T22:57:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bofa-securities-reiterates-buy-rating-on-alnylam-stock-highlights-amvuttra-launch-strategy 2024-10-10T22:57:42+00:00 weekly 0.7 https://trial.medpath.com/news/let-s-talk-breast-density-cancer-movies-and-music-treatment-induced-aging 2024-10-10T21:57:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/let-s-talk-breast-density-cancer-movies-and-music-treatment-induced-aging 2024-10-10T21:57:51+00:00 weekly 0.7 https://trial.medpath.com/news/immatics-heads-to-phase-3-with-melanoma-cell-therapy-seeks-to-raise-150m 2024-10-10T21:42:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immatics-heads-to-phase-3-with-melanoma-cell-therapy-seeks-to-raise-150m 2024-10-10T21:42:42+00:00 weekly 0.7 https://trial.medpath.com/news/an-interactive-game-for-people-suffering-from-nerve-pain-is-heading-to-clinical-trials 2024-10-10T21:22:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-interactive-game-for-people-suffering-from-nerve-pain-is-heading-to-clinical-trials 2024-10-10T21:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/immatics-off-to-phase-iii-with-ima203-after-positive-melanoma-results-scrip-citeline 2024-10-10T21:10:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immatics-off-to-phase-iii-with-ima203-after-positive-melanoma-results-scrip-citeline 2024-10-10T21:10:01+00:00 weekly 0.7 https://trial.medpath.com/news/press-releases-thursday-oct-10-2024-genentech 2024-10-10T21:09:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-releases-thursday-oct-10-2024-genentech 2024-10-10T21:09:57+00:00 weekly 0.7 https://trial.medpath.com/news/drug-rivals-face-off-in-pbc-after-fda-hands-down-2-new-approvals-1-advisory-snub-healio 2024-10-10T20:55:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-rivals-face-off-in-pbc-after-fda-hands-down-2-new-approvals-1-advisory-snub-healio 2024-10-10T20:55:47+00:00 weekly 0.7 https://trial.medpath.com/news/drugmakers-are-racing-to-find-the-next-wegovy-these-obesity-trials-are-ones-to-watch 2024-10-10T20:16:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drugmakers-are-racing-to-find-the-next-wegovy-these-obesity-trials-are-ones-to-watch 2024-10-10T20:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/frontline-egfr-vegf-inhibition-slows-advanced-egfr-positive-lung-cancer 2024-10-10T19:53:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frontline-egfr-vegf-inhibition-slows-advanced-egfr-positive-lung-cancer 2024-10-10T19:53:48+00:00 weekly 0.7 https://trial.medpath.com/news/the-first-ever-antiviral-treatment-for-rsv-american-council-on-science-and-health 2024-10-10T19:27:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-first-ever-antiviral-treatment-for-rsv-american-council-on-science-and-health 2024-10-10T19:27:50+00:00 weekly 0.7 https://trial.medpath.com/news/sotigalimab-may-be-a-safe-and-feasible-addition-to-the-rectal-cancer-chemoradiotherapy 2024-10-10T19:07:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sotigalimab-may-be-a-safe-and-feasible-addition-to-the-rectal-cancer-chemoradiotherapy 2024-10-10T19:07:12+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-and-viiv-healthcare-to-showcase-advances-across-industry-leading-infectious-disease 2024-10-10T19:03:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-and-viiv-healthcare-to-showcase-advances-across-industry-leading-infectious-disease 2024-10-10T19:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-opportunity-for-afib-patients-who-don-t-take-an-anticoagulant-blood-clots 2024-10-10T18:58:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-opportunity-for-afib-patients-who-don-t-take-an-anticoagulant-blood-clots 2024-10-10T18:58:53+00:00 weekly 0.7 https://trial.medpath.com/news/cyrus-biotechnology-congratulates-david-baker-2024-nobel-laureate-in-chemistry-and 2024-10-10T18:38:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cyrus-biotechnology-congratulates-david-baker-2024-nobel-laureate-in-chemistry-and 2024-10-10T18:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/hawai-i-cancer-consortium-expands-clinical-trial-access-to-address-healthcare-disparities-in-pacific-islands 2024-10-10T17:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hawai-i-cancer-consortium-expands-clinical-trial-access-to-address-healthcare-disparities-in-pacific-islands 2024-10-10T17:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/stronger-safety-considerations-needed-for-lumateprone-use-especially-for-women 2024-10-10T17:25:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stronger-safety-considerations-needed-for-lumateprone-use-especially-for-women 2024-10-10T17:25:16+00:00 weekly 0.7 https://trial.medpath.com/news/oxford-hospitals-research-unit-receives-ps1m-funding-bbc 2024-10-10T17:25:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oxford-hospitals-research-unit-receives-ps1m-funding-bbc 2024-10-10T17:25:12+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-iota-biosciences-ide-approval-for-first-in-human-early-feasibility-study-with 2024-10-10T17:25:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-iota-biosciences-ide-approval-for-first-in-human-early-feasibility-study-with 2024-10-10T17:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/bimekizumab-demonstrates-safety-and-efficacy-in-elderly-patients-with-psoriasis 2024-10-10T17:22:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bimekizumab-demonstrates-safety-and-efficacy-in-elderly-patients-with-psoriasis 2024-10-10T17:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/sensorium-therapeutics-highlights-promising-data-on-lead-assets-targeting-anxiety 2024-10-10T16:58:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sensorium-therapeutics-highlights-promising-data-on-lead-assets-targeting-anxiety 2024-10-10T16:58:09+00:00 weekly 0.7 https://trial.medpath.com/news/bayesian-approaches-in-drug-development-continuing-the-virtuous-cycle-nature 2024-10-10T16:00:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayesian-approaches-in-drug-development-continuing-the-virtuous-cycle-nature 2024-10-10T16:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/happy-health-receives-fda-clearance-for-smart-ring-mobihealthnews 2024-10-10T15:44:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/happy-health-receives-fda-clearance-for-smart-ring-mobihealthnews 2024-10-10T15:44:11+00:00 weekly 0.7 https://trial.medpath.com/news/nanoscope-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa-modern-retina 2024-10-10T15:12:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoscope-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa-modern-retina 2024-10-10T15:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-first-of-its-kind-stent-for-neonates-very-young-with-pulmonary-stenosis-approved 2024-10-10T14:54:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q-a-first-of-its-kind-stent-for-neonates-very-young-with-pulmonary-stenosis-approved 2024-10-10T14:54:48+00:00 weekly 0.7 https://trial.medpath.com/news/combination-therapy-may-improve-treatment-response-in-pancreatic-cancer 2024-10-10T14:52:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combination-therapy-may-improve-treatment-response-in-pancreatic-cancer 2024-10-10T14:52:26+00:00 weekly 0.7 https://trial.medpath.com/news/what-you-should-know-about-breakthrough-hiv-drug-futurity 2024-10-10T14:41:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-you-should-know-about-breakthrough-hiv-drug-futurity 2024-10-10T14:41:34+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-study-on-the-intervention-effect-of-digital-therapy-on-children-with-attention-deficit 2024-10-10T14:41:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-study-on-the-intervention-effect-of-digital-therapy-on-children-with-attention-deficit 2024-10-10T14:41:23+00:00 weekly 0.7 https://trial.medpath.com/news/magdalena-biosciences-a-joint-venture-between-jaguar-health-and-filament-health-stock-titan 2024-10-10T14:38:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/magdalena-biosciences-a-joint-venture-between-jaguar-health-and-filament-health-stock-titan 2024-10-10T14:38:11+00:00 weekly 0.7 https://trial.medpath.com/news/antag-therapeutics-gets-fda-clearance-to-start-clinical-trials-with-new-obesity-drug 2024-10-10T14:34:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antag-therapeutics-gets-fda-clearance-to-start-clinical-trials-with-new-obesity-drug 2024-10-10T14:34:19+00:00 weekly 0.7 https://trial.medpath.com/news/forget-epipens-this-san-diego-biotech-is-offering-the-same-medicine-without-needles 2024-10-10T14:31:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/forget-epipens-this-san-diego-biotech-is-offering-the-same-medicine-without-needles 2024-10-10T14:31:46+00:00 weekly 0.7 https://trial.medpath.com/news/7-children-receiving-bluebird-s-gene-therapy-developed-blood-cancers-study 2024-10-10T14:17:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/7-children-receiving-bluebird-s-gene-therapy-developed-blood-cancers-study 2024-10-10T14:17:10+00:00 weekly 0.7 https://trial.medpath.com/news/benmelstobart-plus-anlotinib-in-patients-with-egfr-positive-advanced-nsclc-after-failure-of 2024-10-10T14:16:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/benmelstobart-plus-anlotinib-in-patients-with-egfr-positive-advanced-nsclc-after-failure-of 2024-10-10T14:16:35+00:00 weekly 0.7 https://trial.medpath.com/news/grant-supports-gene-editing-research-for-rare-metabolic-diseases-news-medical 2024-10-10T14:15:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grant-supports-gene-editing-research-for-rare-metabolic-diseases-news-medical 2024-10-10T14:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-phase-iii-prostate-cancer-win-builds-case-for-broader-label-for-talzenna-xtandi-combo 2024-10-10T14:04:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-phase-iii-prostate-cancer-win-builds-case-for-broader-label-for-talzenna-xtandi-combo 2024-10-10T14:04:10+00:00 weekly 0.7 https://trial.medpath.com/news/oncoinvent-announces-first-patient-dosed-in-its-phase-2-clinical-trial-of-radspherin-biospace 2024-10-10T13:58:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncoinvent-announces-first-patient-dosed-in-its-phase-2-clinical-trial-of-radspherin-biospace 2024-10-10T13:58:41+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-analysis-of-durable-responses-on-immune-checkpoint-inhibitors-versus-other 2024-10-10T13:52:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparative-analysis-of-durable-responses-on-immune-checkpoint-inhibitors-versus-other 2024-10-10T13:52:10+00:00 weekly 0.7 https://trial.medpath.com/news/antibiotic-duo-effective-against-drug-resistant-infections-study-kff-health-news 2024-10-10T13:29:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antibiotic-duo-effective-against-drug-resistant-infections-study-kff-health-news 2024-10-10T13:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/highly-targeted-approach-supports-als-gene-therapy-development-als-news-today 2024-10-10T13:27:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/highly-targeted-approach-supports-als-gene-therapy-development-als-news-today 2024-10-10T13:27:38+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-advances-pulsed-field-ablation-clinical-studies-and-launches-new-technology-to 2024-10-10T13:27:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbott-advances-pulsed-field-ablation-clinical-studies-and-launches-new-technology-to 2024-10-10T13:27:30+00:00 weekly 0.7 https://trial.medpath.com/news/tailored-approaches-to-tki-dosing-allow-for-treatment-free-remissions-and-reduced 2024-10-10T13:25:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tailored-approaches-to-tki-dosing-allow-for-treatment-free-remissions-and-reduced 2024-10-10T13:25:32+00:00 weekly 0.7 https://trial.medpath.com/news/clearmind-announces-irb-approval-for-fda-first-in-human-trial-of-cmnd-100-tipranks 2024-10-10T13:09:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clearmind-announces-irb-approval-for-fda-first-in-human-trial-of-cmnd-100-tipranks 2024-10-10T13:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-volixibat-for-cholestatic-pruritus-in-pbc 2024-10-10T13:07:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-volixibat-for-cholestatic-pruritus-in-pbc 2024-10-10T13:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/achieve-life-sciences-announces-completion-of-enrollment-in-orca-ol-clinical-trial-biospace 2024-10-10T13:05:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/achieve-life-sciences-announces-completion-of-enrollment-in-orca-ol-clinical-trial-biospace 2024-10-10T13:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/movano-health-provides-update-on-fda-review-of-eviemed-ring-move-stock-news 2024-10-10T12:50:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/movano-health-provides-update-on-fda-review-of-eviemed-ring-move-stock-news 2024-10-10T12:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/international-myeloma-foundation-launches-clinical-trial-globenewswire 2024-10-10T12:49:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/international-myeloma-foundation-launches-clinical-trial-globenewswire 2024-10-10T12:49:30+00:00 weekly 0.7 https://trial.medpath.com/news/attain-phase-iii-study-of-etirinotecan-pegol-versus-treatment-of-physician-s-choice-in 2024-10-10T12:46:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/attain-phase-iii-study-of-etirinotecan-pegol-versus-treatment-of-physician-s-choice-in 2024-10-10T12:46:41+00:00 weekly 0.7 https://trial.medpath.com/news/ai-simulations-help-drug-trials-forbes 2024-10-10T12:31:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-simulations-help-drug-trials-forbes 2024-10-10T12:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/melt-pharmaceuticals-announces-dosing-of-last-patient-in-pivotal-phase-3-study-of-its-lead 2024-10-10T12:22:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/melt-pharmaceuticals-announces-dosing-of-last-patient-in-pivotal-phase-3-study-of-its-lead 2024-10-10T12:22:48+00:00 weekly 0.7 https://trial.medpath.com/news/a-multicentric-randomized-controlled-clinical-trial-to-study-the-impact-of-bedside-model 2024-10-10T12:07:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-multicentric-randomized-controlled-clinical-trial-to-study-the-impact-of-bedside-model 2024-10-10T12:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/mediwound-announces-phase-ii-head-to-head-study-evaluating-escharex-r-vs-stock-titan 2024-10-10T12:07:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mediwound-announces-phase-ii-head-to-head-study-evaluating-escharex-r-vs-stock-titan 2024-10-10T12:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/micrornas-won-the-nobel-will-they-ever-be-useful-as-medicines-nature 2024-10-10T12:03:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/micrornas-won-the-nobel-will-they-ever-be-useful-as-medicines-nature 2024-10-10T12:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomized-phase-ii-study-of-veliparib-with-temozolomide-or-carboplatin-paclitaxel-versus 2024-10-10T11:55:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-randomized-phase-ii-study-of-veliparib-with-temozolomide-or-carboplatin-paclitaxel-versus 2024-10-10T11:55:22+00:00 weekly 0.7 https://trial.medpath.com/news/priovant-mulls-broad-autoimmune-indications-for-brepacitinib-clinical-trials-arena 2024-10-10T11:49:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/priovant-mulls-broad-autoimmune-indications-for-brepacitinib-clinical-trials-arena 2024-10-10T11:49:10+00:00 weekly 0.7 https://trial.medpath.com/news/tempest-therapeutics-partners-with-roche-on-cancer-trial-investing-com 2024-10-10T11:41:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tempest-therapeutics-partners-with-roche-on-cancer-trial-investing-com 2024-10-10T11:41:54+00:00 weekly 0.7 https://trial.medpath.com/news/ananda-announced-phase-1-clinical-trial-in-australia-hellenic-suffers-further-funding 2024-10-10T11:23:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ananda-announced-phase-1-clinical-trial-in-australia-hellenic-suffers-further-funding 2024-10-10T11:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharming-group-announces-start-of-phase-ii-clinical-trial-globenewswire 2024-10-10T11:02:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharming-group-announces-start-of-phase-ii-clinical-trial-globenewswire 2024-10-10T11:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-to-report-third-quarter-2024-financial-results-and-host-conference-call-on 2024-10-10T10:48:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zymeworks-to-report-third-quarter-2024-financial-results-and-host-conference-call-on 2024-10-10T10:48:17+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-study-identifies-new-targets-for-combating-drug-resistant-cancer-the-statesman 2024-10-10T10:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-study-identifies-new-targets-for-combating-drug-resistant-cancer-the-statesman 2024-10-10T10:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/could-lingering-infection-be-causing-long-covid 2024-10-10T10:10:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-lingering-infection-be-causing-long-covid 2024-10-10T10:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/boys-treated-with-gene-therapy-for-rare-brain-disease-doing-well-6-years-later 2024-10-10T10:10:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boys-treated-with-gene-therapy-for-rare-brain-disease-doing-well-6-years-later 2024-10-10T10:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/new-life-changing-myeloma-drug-approved-for-fourth-line-use-on-the-nhs-for-those 2024-10-10T10:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-life-changing-myeloma-drug-approved-for-fourth-line-use-on-the-nhs-for-those 2024-10-10T10:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/bridget-koontz-md-18f-flotufolastat-demonstrates-high-detection-rate-in-low-psa-setting 2024-10-10T10:01:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridget-koontz-md-18f-flotufolastat-demonstrates-high-detection-rate-in-low-psa-setting 2024-10-10T10:01:54+00:00 weekly 0.7 https://trial.medpath.com/news/experts-emphasize-early-detection-and-personalized-treatment-advances-during-breast-cancer-awareness-month 2024-10-10T10:00:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-emphasize-early-detection-and-personalized-treatment-advances-during-breast-cancer-awareness-month 2024-10-10T10:00:31+00:00 weekly 0.7 https://trial.medpath.com/news/diamedica-gets-sahpra-approval-for-phase-ii-preeclampsia-treatment-trial-yahoo-finance 2024-10-10T09:46:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamedica-gets-sahpra-approval-for-phase-ii-preeclampsia-treatment-trial-yahoo-finance 2024-10-10T09:46:17+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-confirms-acceptance-of-marketing-globenewswire 2024-10-10T09:31:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-medicines-agency-confirms-acceptance-of-marketing-globenewswire 2024-10-10T09:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/low-cost-blood-drug-saves-thousands-of-trauma-patients-lives-nihr 2024-10-10T08:49:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-cost-blood-drug-saves-thousands-of-trauma-patients-lives-nihr 2024-10-10T08:49:08+00:00 weekly 0.7 https://trial.medpath.com/news/study-uncovers-mechanism-of-mx-protein-in-fighting-hiv-1-and-herpes-simplex-virus 2024-10-10T08:22:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-uncovers-mechanism-of-mx-protein-in-fighting-hiv-1-and-herpes-simplex-virus 2024-10-10T08:22:38+00:00 weekly 0.7 https://trial.medpath.com/news/alzecure-pharma-broadcasts-live-event-about-the-phase-ii-candidate-acd440-against 2024-10-10T08:07:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzecure-pharma-broadcasts-live-event-about-the-phase-ii-candidate-acd440-against 2024-10-10T08:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/ab-science-revenues-for-the-first-half-of-2024-and-update-globenewswire 2024-10-10T06:36:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ab-science-revenues-for-the-first-half-of-2024-and-update-globenewswire 2024-10-10T06:36:28+00:00 weekly 0.7 https://trial.medpath.com/news/harbour-biomed-announces-publication-of-the-phase-i-study-results-for-porustobart-morningstar 2024-10-10T06:36:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/harbour-biomed-announces-publication-of-the-phase-i-study-results-for-porustobart-morningstar 2024-10-10T06:36:21+00:00 weekly 0.7 https://trial.medpath.com/news/alexion-astrazeneca-rare-disease-data-at-the-2024-aanem-annual-meeting-and-mgfa 2024-10-10T06:03:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alexion-astrazeneca-rare-disease-data-at-the-2024-aanem-annual-meeting-and-mgfa 2024-10-10T06:03:45+00:00 weekly 0.7 https://trial.medpath.com/news/cantargia-s-phase-ii-results-published-in-clinical-cancer-research-marketscreener 2024-10-10T05:36:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cantargia-s-phase-ii-results-published-in-clinical-cancer-research-marketscreener 2024-10-10T05:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-final-rule-on-laboratory-tests-reshapes-medical-start-up-landscape 2024-10-10T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-final-rule-on-laboratory-tests-reshapes-medical-start-up-landscape 2024-10-10T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/ai-models-show-promise-in-pulmonary-embolism-diagnosis-doximitygpt-achieves-70-accuracy 2024-10-10T05:14:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-models-show-promise-in-pulmonary-embolism-diagnosis-doximitygpt-achieves-70-accuracy 2024-10-10T05:14:34+00:00 weekly 0.7 https://trial.medpath.com/news/protein-prediction-wins-chemistry-nobel-alnylam-submits-an-all-important-drug-application 2024-10-10T04:26:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protein-prediction-wins-chemistry-nobel-alnylam-submits-an-all-important-drug-application 2024-10-10T04:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-completes-v-wave-acquisition-cardiovascular-business 2024-10-10T03:37:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-completes-v-wave-acquisition-cardiovascular-business 2024-10-10T03:37:44+00:00 weekly 0.7 https://trial.medpath.com/news/gummy-drug-delivery-systems-show-promise-for-patient-compliance-face-manufacturing-challenges 2024-10-10T03:27:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gummy-drug-delivery-systems-show-promise-for-patient-compliance-face-manufacturing-challenges 2024-10-10T03:27:26+00:00 weekly 0.7 https://trial.medpath.com/news/activist-investor-starboard-claims-former-pfizer-executives-faced-threats-over-support-for-company-reform 2024-10-10T03:16:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/activist-investor-starboard-claims-former-pfizer-executives-faced-threats-over-support-for-company-reform 2024-10-10T03:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/namodenoson-earns-fda-orphan-drug-designation-in-pancreatic-cancer 2024-10-10T03:03:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/namodenoson-earns-fda-orphan-drug-designation-in-pancreatic-cancer 2024-10-10T03:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/arda-therapeutics-raises-43m-series-a-to-advance-novel-cell-depletion-platform-for-chronic-diseases 2024-10-10T02:00:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arda-therapeutics-raises-43m-series-a-to-advance-novel-cell-depletion-platform-for-chronic-diseases 2024-10-10T02:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/eversana-s-direct-to-patient-model-revolutionizes-healthcare-access-through-digital-innovation 2024-10-10T01:23:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eversana-s-direct-to-patient-model-revolutionizes-healthcare-access-through-digital-innovation 2024-10-10T01:23:38+00:00 weekly 0.7 https://trial.medpath.com/news/purplelab-to-host-webinar-on-data-driven-physician-prescribing-analysis-and-kol-engagement 2024-10-10T00:17:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/purplelab-to-host-webinar-on-data-driven-physician-prescribing-analysis-and-kol-engagement 2024-10-10T00:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/how-tecelra-r-approval-is-transforming-tcr-t-cell-therapy-news-medical 2024-10-10T00:09:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-tecelra-r-approval-is-transforming-tcr-t-cell-therapy-news-medical 2024-10-10T00:09:52+00:00 weekly 0.7 https://trial.medpath.com/news/nih-launches-large-study-to-tackle-type-2-diabetes-in-young-people 2024-10-10T00:02:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-launches-large-study-to-tackle-type-2-diabetes-in-young-people 2024-10-10T00:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/dusseldorf-upc-ruling-clarifies-imminent-infringement-standards-for-biosimilars 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dusseldorf-upc-ruling-clarifies-imminent-infringement-standards-for-biosimilars 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intra-arterial-pressure-enabled-drug-delivery-enhances-liver-tumor-treatment 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intra-arterial-pressure-enabled-drug-delivery-enhances-liver-tumor-treatment 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/emis-wins-innovation-award-for-revolutionary-clinical-trial-recruitment-platform 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emis-wins-innovation-award-for-revolutionary-clinical-trial-recruitment-platform 2024-10-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/digital-clinical-trials-show-promise-in-reducing-costs-despite-implementation-challenges 2024-10-09T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-clinical-trials-show-promise-in-reducing-costs-despite-implementation-challenges 2024-10-09T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/i-20-rehabilitation-project-entering-phase-3-shreveport-ksla 2024-10-09T22:49:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-20-rehabilitation-project-entering-phase-3-shreveport-ksla 2024-10-09T22:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/purespring-secures-105m-to-start-phase-i-ii-trial-of-igan-gene-therapy-clinical-trials-arena 2024-10-09T22:08:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/purespring-secures-105m-to-start-phase-i-ii-trial-of-igan-gene-therapy-clinical-trials-arena 2024-10-09T22:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/kalivir-doses-first-subject-in-phase-i-ib-solid-tumour-treatment-trial 2024-10-09T22:08:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kalivir-doses-first-subject-in-phase-i-ib-solid-tumour-treatment-trial 2024-10-09T22:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/nurse-led-pilot-aims-to-improve-patient-access-to-clinical-trials-nursing-times 2024-10-09T21:50:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurse-led-pilot-aims-to-improve-patient-access-to-clinical-trials-nursing-times 2024-10-09T21:50:54+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-ag-fra-vsc-q2-2024-earnings-call-highlights-strategic-advances-amid-financial 2024-10-09T21:42:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4sc-ag-fra-vsc-q2-2024-earnings-call-highlights-strategic-advances-amid-financial 2024-10-09T21:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-launches-avalus-ultra-valve-in-western-europe-at-eacts-congress 2024-10-09T21:17:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-launches-avalus-ultra-valve-in-western-europe-at-eacts-congress 2024-10-09T21:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/clearside-clears-way-for-phase-iii-after-positive-cls-ax-results-in-wet-amd-scrip 2024-10-09T21:08:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clearside-clears-way-for-phase-iii-after-positive-cls-ax-results-in-wet-amd-scrip 2024-10-09T21:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-biotech-inc-reports-promising-results-for-annamycin-in-aml-treatment 2024-10-09T21:02:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-biotech-inc-reports-promising-results-for-annamycin-in-aml-treatment 2024-10-09T21:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/ai-biotech-insitro-partners-with-lilly-on-metabolic-disease-drugs-endpoints-news 2024-10-09T20:53:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-biotech-insitro-partners-with-lilly-on-metabolic-disease-drugs-endpoints-news 2024-10-09T20:53:14+00:00 weekly 0.7 https://trial.medpath.com/news/a-walk-in-her-flip-flops-el-centro-mayor-shares-story-of-kidney-cancer 2024-10-09T20:28:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-walk-in-her-flip-flops-el-centro-mayor-shares-story-of-kidney-cancer 2024-10-09T20:28:39+00:00 weekly 0.7 https://trial.medpath.com/news/liu-s-insights-on-navigating-the-fragility-of-phase-3-trials-targeted-oncology 2024-10-09T19:03:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/liu-s-insights-on-navigating-the-fragility-of-phase-3-trials-targeted-oncology 2024-10-09T19:03:17+00:00 weekly 0.7 https://trial.medpath.com/news/complex-randomization-delivered-successfully-clinical-leader 2024-10-09T18:48:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/complex-randomization-delivered-successfully-clinical-leader 2024-10-09T18:48:02+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-sunitinib-plus-exemestane-in-post-menopausal-women-with-hormone-receptor 2024-10-09T18:06:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-sunitinib-plus-exemestane-in-post-menopausal-women-with-hormone-receptor 2024-10-09T18:06:44+00:00 weekly 0.7 https://trial.medpath.com/news/schizophrenia-clinical-trial-pipeline-insights-featuring-55-companies-delveinsight 2024-10-09T17:03:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/schizophrenia-clinical-trial-pipeline-insights-featuring-55-companies-delveinsight 2024-10-09T17:03:15+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-potential-to-improve-car-t-therapy-efficiency-using-graphene-oxide 2024-10-09T16:57:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-potential-to-improve-car-t-therapy-efficiency-using-graphene-oxide 2024-10-09T16:57:59+00:00 weekly 0.7 https://trial.medpath.com/news/allurion-s-swallowable-balloon-hits-trial-success-amid-weakening-financials 2024-10-09T16:21:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allurion-s-swallowable-balloon-hits-trial-success-amid-weakening-financials 2024-10-09T16:21:59+00:00 weekly 0.7 https://trial.medpath.com/news/phaxiam-therapeutics-announces-the-validation-of-a-new-investigator-initiated-phase-2-study 2024-10-09T16:15:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phaxiam-therapeutics-announces-the-validation-of-a-new-investigator-initiated-phase-2-study 2024-10-09T16:15:04+00:00 weekly 0.7 https://trial.medpath.com/news/gene-expression-test-may-predict-added-atezolizumab-benefit-in-tnbc-cancer-network 2024-10-09T16:03:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-expression-test-may-predict-added-atezolizumab-benefit-in-tnbc-cancer-network 2024-10-09T16:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/springbok-analytics-receives-fda-510-k-clearance-for-muscleviewtm-its-ai-muscle 2024-10-09T16:00:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/springbok-analytics-receives-fda-510-k-clearance-for-muscleviewtm-its-ai-muscle 2024-10-09T16:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/fast-track-designation-granted-to-liafensine-for-treatment-resistant-depression 2024-10-09T15:49:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fast-track-designation-granted-to-liafensine-for-treatment-resistant-depression 2024-10-09T15:49:39+00:00 weekly 0.7 https://trial.medpath.com/news/multidisciplinary-approach-to-treatment-emerging-techniques-optimize-survival-and 2024-10-09T15:47:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multidisciplinary-approach-to-treatment-emerging-techniques-optimize-survival-and 2024-10-09T15:47:50+00:00 weekly 0.7 https://trial.medpath.com/news/lbl-024-receives-breakthrough-therapy-designation-in-china-for-extrapulmonary-onclive 2024-10-09T15:46:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lbl-024-receives-breakthrough-therapy-designation-in-china-for-extrapulmonary-onclive 2024-10-09T15:46:22+00:00 weekly 0.7 https://trial.medpath.com/news/delivering-on-the-promise-of-living-drugs-roswell-park-comprehensive-cancer-center 2024-10-09T15:32:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delivering-on-the-promise-of-living-drugs-roswell-park-comprehensive-cancer-center 2024-10-09T15:32:29+00:00 weekly 0.7 https://trial.medpath.com/news/assessment-of-fda-premarket-approval-process-and-suggestions-for-improvement-jama-network 2024-10-09T15:29:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/assessment-of-fda-premarket-approval-process-and-suggestions-for-improvement-jama-network 2024-10-09T15:29:55+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-amy-mcmichael-md-discusses-48-week-visible-study-results-on-psoriasis-in 2024-10-09T15:22:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q-a-amy-mcmichael-md-discusses-48-week-visible-study-results-on-psoriasis-in 2024-10-09T15:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/envafolimab-plus-lenvatinib-and-transcatheter-arterial-chemoembolization-for-unresectable 2024-10-09T15:08:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/envafolimab-plus-lenvatinib-and-transcatheter-arterial-chemoembolization-for-unresectable 2024-10-09T15:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/largest-whole-exome-sequencing-study-of-epilepsy-to-date-finds-new-genetic-links 2024-10-09T15:01:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/largest-whole-exome-sequencing-study-of-epilepsy-to-date-finds-new-genetic-links 2024-10-09T15:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/uw-health-eastpark-medical-center-integrates-clinical-trials-into-patient-care-wispolitics 2024-10-09T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uw-health-eastpark-medical-center-integrates-clinical-trials-into-patient-care-wispolitics 2024-10-09T14:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/calluna-pharma-names-ceo 2024-10-09T14:37:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/calluna-pharma-names-ceo 2024-10-09T14:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/viking-therapeutics-reveals-encouraging-data-from-genetic-disorder-drug-study-analyst 2024-10-09T14:13:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viking-therapeutics-reveals-encouraging-data-from-genetic-disorder-drug-study-analyst 2024-10-09T14:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/philly-biotech-to-deliver-first-of-its-kind-cancer-therapy-the-philadelphia-inquirer 2024-10-09T14:09:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/philly-biotech-to-deliver-first-of-its-kind-cancer-therapy-the-philadelphia-inquirer 2024-10-09T14:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/mifepristone-maker-to-seek-fda-ok-for-use-of-drug-to-treat-miscarriages 2024-10-09T13:58:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mifepristone-maker-to-seek-fda-ok-for-use-of-drug-to-treat-miscarriages 2024-10-09T13:58:04+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-s-discovery-suggests-we-already-have-an-fda-approved-treatment 2024-10-09T13:41:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/parkinson-s-discovery-suggests-we-already-have-an-fda-approved-treatment 2024-10-09T13:41:03+00:00 weekly 0.7 https://trial.medpath.com/news/kymera-therapeutics-announces-fda-clearance-of-investigational-new-drug-application 2024-10-09T13:40:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kymera-therapeutics-announces-fda-clearance-of-investigational-new-drug-application 2024-10-09T13:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/longeveron-r-lomecel-btm-5-year-long-term-transplant-free-survival-data-in-hlhs-biospace 2024-10-09T13:40:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longeveron-r-lomecel-btm-5-year-long-term-transplant-free-survival-data-in-hlhs-biospace 2024-10-09T13:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-reaches-midpoint-in-phase-ii-trial-for-topical-gel-r327g 2024-10-09T13:14:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-reaches-midpoint-in-phase-ii-trial-for-topical-gel-r327g 2024-10-09T13:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/ai-squared-awarded-1-5m-phase-iii-small-business-innovative-research-contract-with 2024-10-09T13:07:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-squared-awarded-1-5m-phase-iii-small-business-innovative-research-contract-with 2024-10-09T13:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/can-sure-shot-reduce-the-effects-of-alcohol-clinical-studies-look-promising-forbes 2024-10-09T13:04:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-sure-shot-reduce-the-effects-of-alcohol-clinical-studies-look-promising-forbes 2024-10-09T13:04:41+00:00 weekly 0.7 https://trial.medpath.com/news/alabama-unveils-program-to-expand-free-genetic-testing-clinical-trial-participation 2024-10-09T12:59:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alabama-unveils-program-to-expand-free-genetic-testing-clinical-trial-participation 2024-10-09T12:59:49+00:00 weekly 0.7 https://trial.medpath.com/news/nitches-inc-launches-new-vertical-with-american-made-bioceutical-company-introducing 2024-10-09T12:34:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nitches-inc-launches-new-vertical-with-american-made-bioceutical-company-introducing 2024-10-09T12:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-felzartamab-receives-breakthrough-therapy-designation-quick-facts-rttnews 2024-10-09T12:31:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-felzartamab-receives-breakthrough-therapy-designation-quick-facts-rttnews 2024-10-09T12:31:28+00:00 weekly 0.7 https://trial.medpath.com/news/novos-glp-1-wegovy-could-improve-heart-health-for-millions-more-than-previously 2024-10-09T12:21:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novos-glp-1-wegovy-could-improve-heart-health-for-millions-more-than-previously 2024-10-09T12:21:43+00:00 weekly 0.7 https://trial.medpath.com/news/risk-and-benefit-of-restrictive-transfusion-strategies-in-neurocritically-ill-patients 2024-10-09T12:20:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/risk-and-benefit-of-restrictive-transfusion-strategies-in-neurocritically-ill-patients 2024-10-09T12:20:39+00:00 weekly 0.7 https://trial.medpath.com/news/frequency-of-screening-and-spontaneous-breathing-trial-techniques-a-randomized-clinical-trial 2024-10-09T12:20:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/frequency-of-screening-and-spontaneous-breathing-trial-techniques-a-randomized-clinical-trial 2024-10-09T12:20:30+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-complex-technological-innovations-in-critical-care-jama-network 2024-10-09T12:20:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-complex-technological-innovations-in-critical-care-jama-network 2024-10-09T12:20:28+00:00 weekly 0.7 https://trial.medpath.com/news/stealth-s-ultrarare-disease-candidate-might-not-meet-bar-for-approval-fda-biospace 2024-10-09T12:11:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stealth-s-ultrarare-disease-candidate-might-not-meet-bar-for-approval-fda-biospace 2024-10-09T12:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/viatris-announces-positive-top-line-results-from-phase-3-study-of-effexor-r-in-japanese 2024-10-09T12:08:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viatris-announces-positive-top-line-results-from-phase-3-study-of-effexor-r-in-japanese 2024-10-09T12:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-announces-phase-ii-study-results-of-tyk2-inhibitor-icp-488-meet-primary 2024-10-09T12:05:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innocare-announces-phase-ii-study-results-of-tyk2-inhibitor-icp-488-meet-primary 2024-10-09T12:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/cisplatin-shortage-in-2023-forces-treatment-changes-and-drives-up-costs-in-head-and-neck-cancer-care 2024-10-09T11:52:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cisplatin-shortage-in-2023-forces-treatment-changes-and-drives-up-costs-in-head-and-neck-cancer-care 2024-10-09T11:52:15+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-to-be-presented-at-idweek-2024-reinforce-merck-s-broad-and-diverse-vaccines 2024-10-09T11:25:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-data-to-be-presented-at-idweek-2024-reinforce-merck-s-broad-and-diverse-vaccines 2024-10-09T11:25:04+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-inc-announces-removal-of-clinical-hold-on-investigational-new-drug-application 2024-10-09T11:23:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-inc-announces-removal-of-clinical-hold-on-investigational-new-drug-application 2024-10-09T11:23:09+00:00 weekly 0.7 https://trial.medpath.com/news/scaleready-announces-a-g-rex-r-grant-has-been-awarded-to-lift-biosciences 2024-10-09T11:16:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scaleready-announces-a-g-rex-r-grant-has-been-awarded-to-lift-biosciences 2024-10-09T11:16:42+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-s-updated-2024-2025-nuvaxovidtm-covid-19-vaccine-receives-authorization-in-the-eu 2024-10-09T11:16:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novavax-s-updated-2024-2025-nuvaxovidtm-covid-19-vaccine-receives-authorization-in-the-eu 2024-10-09T11:16:40+00:00 weekly 0.7 https://trial.medpath.com/news/jak-inhibitor-combinations-and-cellular-therapy-shape-future-directions-in-myelofibrosis-treatment 2024-10-09T11:15:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jak-inhibitor-combinations-and-cellular-therapy-shape-future-directions-in-myelofibrosis-treatment 2024-10-09T11:15:05+00:00 weekly 0.7 https://trial.medpath.com/news/gamification-shows-promise-in-boosting-clinical-trial-patient-retention-and-engagement 2024-10-09T11:03:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gamification-shows-promise-in-boosting-clinical-trial-patient-retention-and-engagement 2024-10-09T11:03:50+00:00 weekly 0.7 https://trial.medpath.com/news/the-latest-updates-from-the-gene-editing-clinical-trials-october-2024 2024-10-09T11:02:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-latest-updates-from-the-gene-editing-clinical-trials-october-2024 2024-10-09T11:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/clearside-biomedical-unveils-positive-topline-results-from-odyssey-phase-2b-trial-of 2024-10-09T10:40:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clearside-biomedical-unveils-positive-topline-results-from-odyssey-phase-2b-trial-of 2024-10-09T10:40:04+00:00 weekly 0.7 https://trial.medpath.com/news/indonesia-supports-atmp-research-expands-clinical-trials-antara-news 2024-10-09T10:11:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indonesia-supports-atmp-research-expands-clinical-trials-antara-news 2024-10-09T10:11:18+00:00 weekly 0.7 https://trial.medpath.com/news/buy-rating-for-enanta-pharmaceuticals-amid-reduced-competition-and-promising-drug-trials 2024-10-09T09:33:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/buy-rating-for-enanta-pharmaceuticals-amid-reduced-competition-and-promising-drug-trials 2024-10-09T09:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/regenerative-bioscience-s-meniscus-implant-receives-fda-clearance 2024-10-09T09:22:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regenerative-bioscience-s-meniscus-implant-receives-fda-clearance 2024-10-09T09:22:51+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-how-the-fda-is-approaching-ai-in-clinical-trials-and-drug-development 2024-10-09T08:38:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q-a-how-the-fda-is-approaching-ai-in-clinical-trials-and-drug-development 2024-10-09T08:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/duke-nus-duo-create-precision-tool-for-liver-cancer-mirage-news 2024-10-09T08:36:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/duke-nus-duo-create-precision-tool-for-liver-cancer-mirage-news 2024-10-09T08:36:31+00:00 weekly 0.7 https://trial.medpath.com/news/response-based-intermittent-ibrutinib-dosing-shows-safety-feasibility-in-cll-onclive 2024-10-09T08:08:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/response-based-intermittent-ibrutinib-dosing-shows-safety-feasibility-in-cll-onclive 2024-10-09T08:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/tevogen-bio-highlights-promising-trial-data-as-ceo-leads-patient-advocacy-at-capitol-hill 2024-10-09T08:04:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tevogen-bio-highlights-promising-trial-data-as-ceo-leads-patient-advocacy-at-capitol-hill 2024-10-09T08:04:28+00:00 weekly 0.7 https://trial.medpath.com/news/kineta-announces-completion-of-enrollment-in-the-monotherapy-arm-of-the-vista-101-biospace 2024-10-09T07:07:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kineta-announces-completion-of-enrollment-in-the-monotherapy-arm-of-the-vista-101-biospace 2024-10-09T07:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/genetic-study-reveals-one-way-link-between-cardiovascular-disease-and-psoriasis-risk 2024-10-09T07:00:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genetic-study-reveals-one-way-link-between-cardiovascular-disease-and-psoriasis-risk 2024-10-09T07:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/fast-news-cspc-pharma-s-urticaria-drug-approved-in-china-bamboo-works 2024-10-09T05:54:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fast-news-cspc-pharma-s-urticaria-drug-approved-in-china-bamboo-works 2024-10-09T05:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/the-impact-of-fu-s-subcutaneous-needling-on-lower-limb-muscle-stiffnes-jpr 2024-10-09T05:18:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-impact-of-fu-s-subcutaneous-needling-on-lower-limb-muscle-stiffnes-jpr 2024-10-09T05:18:42+00:00 weekly 0.7 https://trial.medpath.com/news/closed-loop-medicine-pioneers-precision-medicine-through-drug-software-integration 2024-10-09T05:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/closed-loop-medicine-pioneers-precision-medicine-through-drug-software-integration 2024-10-09T05:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-epigenetic-liquid-biopsy-platform-shows-promise-in-detecting-psma-expression-for-prostate-cancer-treatment 2024-10-09T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-epigenetic-liquid-biopsy-platform-shows-promise-in-detecting-psma-expression-for-prostate-cancer-treatment 2024-10-09T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sexual-health-and-quality-of-life-with-simple-vs-radical-hysterectomy-in-low-risk-early 2024-10-09T04:53:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sexual-health-and-quality-of-life-with-simple-vs-radical-hysterectomy-in-low-risk-early 2024-10-09T04:53:54+00:00 weekly 0.7 https://trial.medpath.com/news/personalized-medicine-emerges-as-key-to-future-multiple-myeloma-treatment-success 2024-10-09T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/personalized-medicine-emerges-as-key-to-future-multiple-myeloma-treatment-success 2024-10-09T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/stealth-s-elamipretide-efficacy-in-barth-syndrome-not-shown-us-fda-says-pink-sheet 2024-10-09T03:25:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stealth-s-elamipretide-efficacy-in-barth-syndrome-not-shown-us-fda-says-pink-sheet 2024-10-09T03:25:08+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-progresses-phase-2-trial-for-bacterial-skin-infections-passing 2024-10-09T03:06:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-progresses-phase-2-trial-for-bacterial-skin-infections-passing 2024-10-09T03:06:55+00:00 weekly 0.7 https://trial.medpath.com/news/dermata-therapeutics-to-participate-in-the-2024-maxim-healthcare-virtual-summit-on-quantisnow 2024-10-09T02:33:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dermata-therapeutics-to-participate-in-the-2024-maxim-healthcare-virtual-summit-on-quantisnow 2024-10-09T02:33:08+00:00 weekly 0.7 https://trial.medpath.com/news/clarity-enters-a-clinical-manufacturing-agreement-for-cu-64-sar-bispsma-with-spectronrx 2024-10-09T02:31:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clarity-enters-a-clinical-manufacturing-agreement-for-cu-64-sar-bispsma-with-spectronrx 2024-10-09T02:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/sage-nmda-modulator-fails-in-alzheimer-s-months-after-parkinson-s-disappointment-scrip 2024-10-09T02:00:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-nmda-modulator-fails-in-alzheimer-s-months-after-parkinson-s-disappointment-scrip 2024-10-09T02:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/danco-laboratories-to-seek-fda-approval-for-mifepristone-in-miscarriage-management 2024-10-09T01:28:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/danco-laboratories-to-seek-fda-approval-for-mifepristone-in-miscarriage-management 2024-10-09T01:28:31+00:00 weekly 0.7 https://trial.medpath.com/news/recon-gsk-pfizer-rsv-vaccine-sales-drop-in-the-us-sage-abandons-alzheimer-s-drug 2024-10-09T01:12:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recon-gsk-pfizer-rsv-vaccine-sales-drop-in-the-us-sage-abandons-alzheimer-s-drug 2024-10-09T01:12:14+00:00 weekly 0.7 https://trial.medpath.com/news/globus-medical-in-2024-6-notes 2024-10-09T00:48:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/globus-medical-in-2024-6-notes 2024-10-09T00:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-second-crl-for-dasiglucagon-to-treat-hypoglycemia-in-congenital-hyperinsulinism 2024-10-09T00:11:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-second-crl-for-dasiglucagon-to-treat-hypoglycemia-in-congenital-hyperinsulinism 2024-10-09T00:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-clinical-trial-designs-for-assessing-treatment-effects-on-kidney-function 2024-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-clinical-trial-designs-for-assessing-treatment-effects-on-kidney-function 2024-10-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/why-soleno-therapeutics-stock-blasted-9-higher-today-the-globe-and-mail 2024-10-08T23:27:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-soleno-therapeutics-stock-blasted-9-higher-today-the-globe-and-mail 2024-10-08T23:27:40+00:00 weekly 0.7 https://trial.medpath.com/news/5-year-outcomes-add-supportive-evidence-to-approved-gene-therapy-for-duchenne 2024-10-08T22:52:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-year-outcomes-add-supportive-evidence-to-approved-gene-therapy-for-duchenne 2024-10-08T22:52:16+00:00 weekly 0.7 https://trial.medpath.com/news/basecamp-research-secures-60m-and-partners-with-broad-institute-to-advance-ai-driven-genetic-medicine 2024-10-08T22:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/basecamp-research-secures-60m-and-partners-with-broad-institute-to-advance-ai-driven-genetic-medicine 2024-10-08T22:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-ad-comm-to-consider-rare-disease-treatment-amid-advocacy-push-fda-efficacy-concerns 2024-10-08T21:14:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-ad-comm-to-consider-rare-disease-treatment-amid-advocacy-push-fda-efficacy-concerns 2024-10-08T21:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/pulmonology-month-in-review-september-2024-hcplive 2024-10-08T21:03:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pulmonology-month-in-review-september-2024-hcplive 2024-10-08T21:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/lab-data-analytics-revolutionizes-patient-identification-and-treatment-targeting-in-pharma-industry 2024-10-08T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lab-data-analytics-revolutionizes-patient-identification-and-treatment-targeting-in-pharma-industry 2024-10-08T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4c-medical-commences-enrollment-in-heart-valve-trial-massdevice 2024-10-08T20:47:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4c-medical-commences-enrollment-in-heart-valve-trial-massdevice 2024-10-08T20:47:47+00:00 weekly 0.7 https://trial.medpath.com/news/new-subgroup-analyses-from-landmark-phase-3-aspen-study-of-brensocatib-in-patients 2024-10-08T20:38:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-subgroup-analyses-from-landmark-phase-3-aspen-study-of-brensocatib-in-patients 2024-10-08T20:38:40+00:00 weekly 0.7 https://trial.medpath.com/news/aviadobio-and-astellas-ink-potential-2-5b-deal-for-frontotemporal-dementia-candidate 2024-10-08T20:37:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aviadobio-and-astellas-ink-potential-2-5b-deal-for-frontotemporal-dementia-candidate 2024-10-08T20:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/former-columbia-university-psychiatrist-committed-research-misconduct-says-federal-watchdog 2024-10-08T19:15:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/former-columbia-university-psychiatrist-committed-research-misconduct-says-federal-watchdog 2024-10-08T19:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/vici-health-sciences-announces-launch-of-phase-i-phase-ii-and-phase-iii-clinical-supplies 2024-10-08T18:58:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vici-health-sciences-announces-launch-of-phase-i-phase-ii-and-phase-iii-clinical-supplies 2024-10-08T18:58:50+00:00 weekly 0.7 https://trial.medpath.com/news/fourth-non-browning-apple-made-in-summerland-gets-fda-approval-vancouver-sun 2024-10-08T18:58:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fourth-non-browning-apple-made-in-summerland-gets-fda-approval-vancouver-sun 2024-10-08T18:58:40+00:00 weekly 0.7 https://trial.medpath.com/news/mindbio-develops-long-term-shelf-stable-microdosing-formulation-and-is-progressing-in 2024-10-08T18:14:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mindbio-develops-long-term-shelf-stable-microdosing-formulation-and-is-progressing-in 2024-10-08T18:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/lifesciences-and-healthcare-newsletter-august-2024-life-sciences-biotechnology 2024-10-08T18:13:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lifesciences-and-healthcare-newsletter-august-2024-life-sciences-biotechnology 2024-10-08T18:13:06+00:00 weekly 0.7 https://trial.medpath.com/news/adc-and-cdk4-6-inhibitor-decision-making-and-sequencing-questions-abound-in-breast-cancer 2024-10-08T18:08:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adc-and-cdk4-6-inhibitor-decision-making-and-sequencing-questions-abound-in-breast-cancer 2024-10-08T18:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/sage-continues-downslide-as-alzheimer-s-study-fails-biopharma-dive 2024-10-08T17:21:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-continues-downslide-as-alzheimer-s-study-fails-biopharma-dive 2024-10-08T17:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/french-agency-places-novo-nordisk-s-anti-obesity-drug-under-close-surveillance-euractiv 2024-10-08T16:22:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/french-agency-places-novo-nordisk-s-anti-obesity-drug-under-close-surveillance-euractiv 2024-10-08T16:22:48+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-late-breaking-abstract-accepted-for-oral-presentation-on-v007-phase-3-av-biospace 2024-10-08T16:15:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-late-breaking-abstract-accepted-for-oral-presentation-on-v007-phase-3-av-biospace 2024-10-08T16:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/startup-led-by-john-maraganore-raises-135m-to-build-future-of-rnai-biopharma-dive 2024-10-08T16:06:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/startup-led-by-john-maraganore-raises-135m-to-build-future-of-rnai-biopharma-dive 2024-10-08T16:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/srrk-stock-soars-as-muscle-disease-drug-meets-phase-iii-study-goal-barchart-com 2024-10-08T16:05:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/srrk-stock-soars-as-muscle-disease-drug-meets-phase-iii-study-goal-barchart-com 2024-10-08T16:05:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-ai-powered-aortic-stenosis-screening-tool 2024-10-08T15:38:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-ai-powered-aortic-stenosis-screening-tool 2024-10-08T15:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/gastrointestinal-medical-oncologist-and-researcher-driven-to-help-patients-live-longer 2024-10-08T15:08:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gastrointestinal-medical-oncologist-and-researcher-driven-to-help-patients-live-longer 2024-10-08T15:08:23+00:00 weekly 0.7 https://trial.medpath.com/news/dr-reddy-s-unit-achieves-trial-breakthrough-positive-results-for-blood-cancer-treatment 2024-10-08T14:26:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-reddy-s-unit-achieves-trial-breakthrough-positive-results-for-blood-cancer-treatment 2024-10-08T14:26:18+00:00 weekly 0.7 https://trial.medpath.com/news/parp1-selective-inhibitors-generate-excitement-in-solid-tumors-onclive 2024-10-08T14:21:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/parp1-selective-inhibitors-generate-excitement-in-solid-tumors-onclive 2024-10-08T14:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/who-updates-cervical-cancer-prevention-guidelines-oncology-nursing-news 2024-10-08T14:03:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-updates-cervical-cancer-prevention-guidelines-oncology-nursing-news 2024-10-08T14:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/interpreting-modern-randomized-controlled-trials-of-medical-therapy-in-inflammatory-bowel-disease 2024-10-08T13:57:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/interpreting-modern-randomized-controlled-trials-of-medical-therapy-in-inflammatory-bowel-disease 2024-10-08T13:57:12+00:00 weekly 0.7 https://trial.medpath.com/news/adcendo-announces-us-fda-clearance-of-ind-application-for-phase-i-ii-first-in-human 2024-10-08T13:30:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adcendo-announces-us-fda-clearance-of-ind-application-for-phase-i-ii-first-in-human 2024-10-08T13:30:43+00:00 weekly 0.7 https://trial.medpath.com/news/pharmala-to-supply-the-university-of-texas-san-antonio-with-novel-dosage-form-of-laneotm-mdma 2024-10-08T13:15:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmala-to-supply-the-university-of-texas-san-antonio-with-novel-dosage-form-of-laneotm-mdma 2024-10-08T13:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/oragenics-inc-successfully-completes-key-fda-recognized-study-for-onp-002 2024-10-08T13:12:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oragenics-inc-successfully-completes-key-fda-recognized-study-for-onp-002 2024-10-08T13:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/biosimilar-rituximab-safe-effective-for-sle-after-switching 2024-10-08T13:09:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biosimilar-rituximab-safe-effective-for-sle-after-switching 2024-10-08T13:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/all-the-news-that-s-fit-alzheimer-s-drug-study-rice-balls-record-and-hawking-s-words 2024-10-08T12:44:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/all-the-news-that-s-fit-alzheimer-s-drug-study-rice-balls-record-and-hawking-s-words 2024-10-08T12:44:06+00:00 weekly 0.7 https://trial.medpath.com/news/pierre-fabre-laboratories-and-scorpion-therapeutics-announce-first-patient-dosed-in 2024-10-08T12:38:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pierre-fabre-laboratories-and-scorpion-therapeutics-announce-first-patient-dosed-in 2024-10-08T12:38:05+00:00 weekly 0.7 https://trial.medpath.com/news/teva-pharma-fda-to-review-bla-for-tvb-009p-quick-facts-markets-insider 2024-10-08T12:37:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-pharma-fda-to-review-bla-for-tvb-009p-quick-facts-markets-insider 2024-10-08T12:37:46+00:00 weekly 0.7 https://trial.medpath.com/news/avalo-announces-first-patient-dosed-in-phase-2-lotus-trial-of-avtx-009-for-the-treatment 2024-10-08T12:36:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avalo-announces-first-patient-dosed-in-phase-2-lotus-trial-of-avtx-009-for-the-treatment 2024-10-08T12:36:26+00:00 weekly 0.7 https://trial.medpath.com/news/sage-therapeutics-announces-topline-results-from-the-phase-2-lightwave-study-of-biospace 2024-10-08T12:36:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-therapeutics-announces-topline-results-from-the-phase-2-lightwave-study-of-biospace 2024-10-08T12:36:07+00:00 weekly 0.7 https://trial.medpath.com/news/rgenta-therapeutics-announces-first-patients-dosed-in-phase-1a-b-clinical-trial-of-rgt 2024-10-08T12:15:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rgenta-therapeutics-announces-first-patients-dosed-in-phase-1a-b-clinical-trial-of-rgt 2024-10-08T12:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/nkgen-biotech-announces-poster-presentations-at-the-17th-globenewswire 2024-10-08T12:10:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nkgen-biotech-announces-poster-presentations-at-the-17th-globenewswire 2024-10-08T12:10:33+00:00 weekly 0.7 https://trial.medpath.com/news/verismo-therapeutics-announces-the-activation-of-its-celestial-301-clinical-trial-at 2024-10-08T12:05:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verismo-therapeutics-announces-the-activation-of-its-celestial-301-clinical-trial-at 2024-10-08T12:05:32+00:00 weekly 0.7 https://trial.medpath.com/news/avextra-announces-the-approval-of-neurobis-by-the-italian-globenewswire 2024-10-08T11:12:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avextra-announces-the-approval-of-neurobis-by-the-italian-globenewswire 2024-10-08T11:12:59+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-discontinues-phase-iii-study-of-treatment-for-bladder-cancer 2024-10-08T10:42:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-discontinues-phase-iii-study-of-treatment-for-bladder-cancer 2024-10-08T10:42:17+00:00 weekly 0.7 https://trial.medpath.com/news/sustained-effect-of-prasinezumab-on-parkinson-s-disease-motor-progression-in-the-open-nature 2024-10-08T10:25:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sustained-effect-of-prasinezumab-on-parkinson-s-disease-motor-progression-in-the-open-nature 2024-10-08T10:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/eu-notified-body-bsi-netherlands-and-the-ema-grant-approval-of-the-leukostrat-r-cdx 2024-10-08T10:24:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-notified-body-bsi-netherlands-and-the-ema-grant-approval-of-the-leukostrat-r-cdx 2024-10-08T10:24:29+00:00 weekly 0.7 https://trial.medpath.com/news/could-music-lessons-help-clear-the-brain-fog-of-chemotherapy 2024-10-08T10:10:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-music-lessons-help-clear-the-brain-fog-of-chemotherapy 2024-10-08T10:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/kyowa-kirin-announces-positive-interim-real-world-data-for-mogamulizumab-poteligeo 2024-10-08T10:02:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kyowa-kirin-announces-positive-interim-real-world-data-for-mogamulizumab-poteligeo 2024-10-08T10:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/ai-enabled-remote-cardiac-monitoring-reveals-critical-link-between-sleep-and-heart-health 2024-10-08T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-enabled-remote-cardiac-monitoring-reveals-critical-link-between-sleep-and-heart-health 2024-10-08T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/scholar-rock-heading-to-finish-line-in-sma-with-positive-pivotal-data-scrip-citeline 2024-10-08T09:49:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scholar-rock-heading-to-finish-line-in-sma-with-positive-pivotal-data-scrip-citeline 2024-10-08T09:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/fish-skin-grafts-outperform-current-treatments-in-diabetic-foot-ulcers-clinical-trials-arena 2024-10-08T09:47:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fish-skin-grafts-outperform-current-treatments-in-diabetic-foot-ulcers-clinical-trials-arena 2024-10-08T09:47:35+00:00 weekly 0.7 https://trial.medpath.com/news/nch-health-rooney-heart-institute-announces-successful-clinical-trial 2024-10-08T09:31:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nch-health-rooney-heart-institute-announces-successful-clinical-trial 2024-10-08T09:31:26+00:00 weekly 0.7 https://trial.medpath.com/news/consideration-of-factors-of-low-accrual-and-methods-for-setting-appropriate-accrual-periods 2024-10-08T08:29:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/consideration-of-factors-of-low-accrual-and-methods-for-setting-appropriate-accrual-periods 2024-10-08T08:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/survey-reveals-strong-allergist-support-for-biologics-in-food-allergy-treatment-despite-cost-concerns 2024-10-08T08:07:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/survey-reveals-strong-allergist-support-for-biologics-in-food-allergy-treatment-despite-cost-concerns 2024-10-08T08:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/zealand-pharma-announces-that-boehringer-receives-u-s-fda-breakthrough-therapy 2024-10-08T06:46:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zealand-pharma-announces-that-boehringer-receives-u-s-fda-breakthrough-therapy 2024-10-08T06:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/apitegromab-shows-promise-in-phase-iii-spinal-muscular-atrophy-trial-scholar-rock-reports 2024-10-08T06:17:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apitegromab-shows-promise-in-phase-iii-spinal-muscular-atrophy-trial-scholar-rock-reports 2024-10-08T06:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/kronos-bio-announces-selection-of-autoimmune-development-candidate-for-sjogren-s-disease 2024-10-08T05:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kronos-bio-announces-selection-of-autoimmune-development-candidate-for-sjogren-s-disease 2024-10-08T05:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/sk-biopharm-and-eurofarma-submit-nda-for-epilepsy-drug-in-brazil-businesskorea 2024-10-08T05:16:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sk-biopharm-and-eurofarma-submit-nda-for-epilepsy-drug-in-brazil-businesskorea 2024-10-08T05:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/cybrexa-therapeutics-announces-first-patient-dosed-with-first-in-class-peptide-drug-biospace 2024-10-08T05:12:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cybrexa-therapeutics-announces-first-patient-dosed-with-first-in-class-peptide-drug-biospace 2024-10-08T05:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/alzamend-neuro-partners-with-massachusetts-general-hospital-for-a-phase-ii-clinical-trial 2024-10-08T04:35:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzamend-neuro-partners-with-massachusetts-general-hospital-for-a-phase-ii-clinical-trial 2024-10-08T04:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/glytherix-and-eckert-ziegler-sign-agreement-for-lutetium-177-supply 2024-10-08T02:38:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glytherix-and-eckert-ziegler-sign-agreement-for-lutetium-177-supply 2024-10-08T02:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-announces-positive-results-from-long-term-treatment-studies-and-updates-on-regulatory-progress-for-vatiquinone-friedreich-ataxia-program 2024-10-08T02:10:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptc-therapeutics-announces-positive-results-from-long-term-treatment-studies-and-updates-on-regulatory-progress-for-vatiquinone-friedreich-ataxia-program 2024-10-08T02:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/inspire-trial-investigates-immunotherapy-for-molecularly-selected-advanced-prostate-cancer 2024-10-08T01:09:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inspire-trial-investigates-immunotherapy-for-molecularly-selected-advanced-prostate-cancer 2024-10-08T01:09:05+00:00 weekly 0.7 https://trial.medpath.com/news/orthocell-garners-regulatory-approval-for-remplir-in-gateway-asian-market-of-singapore 2024-10-08T00:57:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/orthocell-garners-regulatory-approval-for-remplir-in-gateway-asian-market-of-singapore 2024-10-08T00:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-authorizes-marketing-of-first-home-flu-and-covid-19-combination-test-outside-of 2024-10-08T00:19:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-authorizes-marketing-of-first-home-flu-and-covid-19-combination-test-outside-of 2024-10-08T00:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/stereotactic-ablative-radiotherapy-shows-promise-in-pancreatic-cancer-treatment-while-phase-3-trial-questions-chemoradiation-benefits 2024-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stereotactic-ablative-radiotherapy-shows-promise-in-pancreatic-cancer-treatment-while-phase-3-trial-questions-chemoradiation-benefits 2024-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-ai-helps-boost-breast-screening-accuracy 2024-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-shows-ai-helps-boost-breast-screening-accuracy 2024-10-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ascentage-pharma-s-apg-2449-advances-to-phase-iii-tipranks-com 2024-10-07T23:49:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascentage-pharma-s-apg-2449-advances-to-phase-iii-tipranks-com 2024-10-07T23:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/insignis-therapeutics-announces-positive-results-from-phase-1-clinical-study-of-in-001 2024-10-07T22:46:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insignis-therapeutics-announces-positive-results-from-phase-1-clinical-study-of-in-001 2024-10-07T22:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/tci-unveils-promising-glp-1-formula-clinical-trial-results-for-advanced-weight-management 2024-10-07T22:10:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tci-unveils-promising-glp-1-formula-clinical-trial-results-for-advanced-weight-management 2024-10-07T22:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/scholar-rock-drug-for-spinal-muscular-atrophy-succeeds-in-late-stage-study-stat-news 2024-10-07T21:49:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scholar-rock-drug-for-spinal-muscular-atrophy-succeeds-in-late-stage-study-stat-news 2024-10-07T21:49:47+00:00 weekly 0.7 https://trial.medpath.com/news/elanco-receives-fda-approval-for-credelio-quattrotm-lotilaner-moxidectin-praziquantel 2024-10-07T20:22:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elanco-receives-fda-approval-for-credelio-quattrotm-lotilaner-moxidectin-praziquantel 2024-10-07T20:22:17+00:00 weekly 0.7 https://trial.medpath.com/news/procept-biorobotics-received-u-s-fda-approval-to-initiate-globenewswire 2024-10-07T20:10:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/procept-biorobotics-received-u-s-fda-approval-to-initiate-globenewswire 2024-10-07T20:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/nurses-are-critical-partners-in-the-clinical-trial-process-oncology-nursing-news 2024-10-07T19:11:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurses-are-critical-partners-in-the-clinical-trial-process-oncology-nursing-news 2024-10-07T19:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/recruitment-of-emergency-department-patients-to-a-prospective-observational-study 2024-10-07T18:39:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recruitment-of-emergency-department-patients-to-a-prospective-observational-study 2024-10-07T18:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/biodefense-headlines-7-october-2024 2024-10-07T18:35:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biodefense-headlines-7-october-2024 2024-10-07T18:35:44+00:00 weekly 0.7 https://trial.medpath.com/news/neuvivo-seeks-fda-approval-for-its-breakthrough-als-treatment-np001 2024-10-07T18:10:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuvivo-seeks-fda-approval-for-its-breakthrough-als-treatment-np001 2024-10-07T18:10:21+00:00 weekly 0.7 https://trial.medpath.com/news/gotistobart-plus-pembrolizumab-shows-activity-in-platinum-resistant-ovarian-cancer 2024-10-07T18:01:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gotistobart-plus-pembrolizumab-shows-activity-in-platinum-resistant-ovarian-cancer 2024-10-07T18:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-cancer-vaccine-blocks-tumor-progression-at-early-lesion-stage-vumc-news 2024-10-07T17:51:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-shows-cancer-vaccine-blocks-tumor-progression-at-early-lesion-stage-vumc-news 2024-10-07T17:51:19+00:00 weekly 0.7 https://trial.medpath.com/news/the-biotech-news-stories-you-need-to-read-this-morning 2024-10-07T17:31:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-biotech-news-stories-you-need-to-read-this-morning 2024-10-07T17:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/substantial-delays-in-postapproval-pediatric-testing-for-new-drugs 2024-10-07T16:43:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/substantial-delays-in-postapproval-pediatric-testing-for-new-drugs 2024-10-07T16:43:55+00:00 weekly 0.7 https://trial.medpath.com/news/therapeutic-antibodies-against-the-marburg-virus-tu-braunschweig-blogs 2024-10-07T16:43:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/therapeutic-antibodies-against-the-marburg-virus-tu-braunschweig-blogs 2024-10-07T16:43:10+00:00 weekly 0.7 https://trial.medpath.com/news/having-trouble-quitting-vaping-you-re-not-the-only-one-time 2024-10-07T16:25:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/having-trouble-quitting-vaping-you-re-not-the-only-one-time 2024-10-07T16:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/2-minute-medicine-rewind-october-7-2024 2024-10-07T16:15:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2-minute-medicine-rewind-october-7-2024 2024-10-07T16:15:24+00:00 weekly 0.7 https://trial.medpath.com/news/bringing-research-to-patients-home-to-improve-quality-of-life-in-palliative-care-nihr 2024-10-07T16:15:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bringing-research-to-patients-home-to-improve-quality-of-life-in-palliative-care-nihr 2024-10-07T16:15:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-taps-urmc-to-develop-new-digital-measures-for-huntington-s-disease 2024-10-07T16:09:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-taps-urmc-to-develop-new-digital-measures-for-huntington-s-disease 2024-10-07T16:09:02+00:00 weekly 0.7 https://trial.medpath.com/news/gbi-biomanufacturing-and-allterum-therapeutics-announce-strategic-collaboration-to 2024-10-07T16:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gbi-biomanufacturing-and-allterum-therapeutics-announce-strategic-collaboration-to 2024-10-07T16:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/trial-of-kezar-s-only-active-drug-halted-after-five-patients-die-scrip-citeline 2024-10-07T16:01:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-of-kezar-s-only-active-drug-halted-after-five-patients-die-scrip-citeline 2024-10-07T16:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-tools-for-assessing-bias-in-a-meta-analysis-of-clinical-trials-on-race-and-ras 2024-10-07T15:45:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-tools-for-assessing-bias-in-a-meta-analysis-of-clinical-trials-on-race-and-ras 2024-10-07T15:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/indivior-s-sublocade-r-rapid-induction-alternative-injection-site-prior-approval-pr-newswire 2024-10-07T15:32:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indivior-s-sublocade-r-rapid-induction-alternative-injection-site-prior-approval-pr-newswire 2024-10-07T15:32:50+00:00 weekly 0.7 https://trial.medpath.com/news/circulating-tumor-cell-count-and-overall-survival-in-patients-with-metastatic-hormone 2024-10-07T15:30:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/circulating-tumor-cell-count-and-overall-survival-in-patients-with-metastatic-hormone 2024-10-07T15:30:06+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-biologists-discover-a-new-mechanism-for-an-old-drug-mit-news 2024-10-07T15:28:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-biologists-discover-a-new-mechanism-for-an-old-drug-mit-news 2024-10-07T15:28:22+00:00 weekly 0.7 https://trial.medpath.com/news/testing-of-new-drugs-approved-from-2015-to-2021-under-the-us-pediatric-research-equity-act 2024-10-07T15:11:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/testing-of-new-drugs-approved-from-2015-to-2021-under-the-us-pediatric-research-equity-act 2024-10-07T15:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-tools-for-assessing-bias-in-a-meta-analysis-of-clinical-trials-on-race-and-ras-blockade 2024-10-07T15:11:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-tools-for-assessing-bias-in-a-meta-analysis-of-clinical-trials-on-race-and-ras-blockade 2024-10-07T15:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/are-people-holding-their-arms-incorrectly-for-blood-pressure-tests 2024-10-07T15:10:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/are-people-holding-their-arms-incorrectly-for-blood-pressure-tests 2024-10-07T15:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/early-blood-test-can-predict-survival-in-men-newly-diagnosed-with-metastatic-prostate-cancer 2024-10-07T15:08:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-blood-test-can-predict-survival-in-men-newly-diagnosed-with-metastatic-prostate-cancer 2024-10-07T15:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-announces-abstract-that-highlights-leronlimab-s-potential-in-mediating-art-free 2024-10-07T15:06:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytodyn-announces-abstract-that-highlights-leronlimab-s-potential-in-mediating-art-free 2024-10-07T15:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/us-scientists-win-nobel-prize-for-gene-regulation-breakthrough-punch-newspapers 2024-10-07T14:56:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-scientists-win-nobel-prize-for-gene-regulation-breakthrough-punch-newspapers 2024-10-07T14:56:09+00:00 weekly 0.7 https://trial.medpath.com/news/protac-protein-degraders-to-drug-the-undruggable-enter-phase-3-trials-nature 2024-10-07T14:31:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protac-protein-degraders-to-drug-the-undruggable-enter-phase-3-trials-nature 2024-10-07T14:31:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-3-tubes-of-aminolevulinic-acid-hydrochloride-for-actinic-keratosis-hcplive 2024-10-07T14:29:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-3-tubes-of-aminolevulinic-acid-hydrochloride-for-actinic-keratosis-hcplive 2024-10-07T14:29:46+00:00 weekly 0.7 https://trial.medpath.com/news/senex-biotechnology-receives-notice-of-allowance-for-novel-cdk8-19-inhibitors-from-benzinga 2024-10-07T14:24:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senex-biotechnology-receives-notice-of-allowance-for-novel-cdk8-19-inhibitors-from-benzinga 2024-10-07T14:24:28+00:00 weekly 0.7 https://trial.medpath.com/news/results-and-outcome-of-the-aegean-trial-targeted-oncology 2024-10-07T14:21:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/results-and-outcome-of-the-aegean-trial-targeted-oncology 2024-10-07T14:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/united-states-supreme-court-declines-to-review-rulings-that-invalidate-united-therapeutics-patent 2024-10-07T14:05:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/united-states-supreme-court-declines-to-review-rulings-that-invalidate-united-therapeutics-patent 2024-10-07T14:05:28+00:00 weekly 0.7 https://trial.medpath.com/news/alk-abello-announces-fda-approval-of-accutest-allergy-skin-testing-devices-tipranks 2024-10-07T13:44:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alk-abello-announces-fda-approval-of-accutest-allergy-skin-testing-devices-tipranks 2024-10-07T13:44:27+00:00 weekly 0.7 https://trial.medpath.com/news/the-nimml-institute-and-nimmune-biopharma-announce-publication-of-new-mechanistic 2024-10-07T13:43:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-nimml-institute-and-nimmune-biopharma-announce-publication-of-new-mechanistic 2024-10-07T13:43:44+00:00 weekly 0.7 https://trial.medpath.com/news/new-government-tech-deals-boost-the-business-of-cancer-detection-wired-gov 2024-10-07T13:35:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-government-tech-deals-boost-the-business-of-cancer-detection-wired-gov 2024-10-07T13:35:36+00:00 weekly 0.7 https://trial.medpath.com/news/continuous-lateral-rotation-therapy-in-mv-does-not-affect-mortality-los 2024-10-07T13:31:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/continuous-lateral-rotation-therapy-in-mv-does-not-affect-mortality-los 2024-10-07T13:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-status-to-ultragenyx-s-osteogenesis-imperfecta-drug 2024-10-07T13:21:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-status-to-ultragenyx-s-osteogenesis-imperfecta-drug 2024-10-07T13:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/scholar-rock-s-phase-3-sapphire-study-of-apitegromab-in-sma-meets-primary-goal-stock-surges 2024-10-07T13:14:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scholar-rock-s-phase-3-sapphire-study-of-apitegromab-in-sma-meets-primary-goal-stock-surges 2024-10-07T13:14:38+00:00 weekly 0.7 https://trial.medpath.com/news/neuvivo-seeks-fda-approval-for-its-breakthrough-als-treatment-np001-yahoo-finance 2024-10-07T13:08:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neuvivo-seeks-fda-approval-for-its-breakthrough-als-treatment-np001-yahoo-finance 2024-10-07T13:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/largest-lung-cancer-clinical-trial-starts-to-recruit-patients-at-the-christie 2024-10-07T13:08:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/largest-lung-cancer-clinical-trial-starts-to-recruit-patients-at-the-christie 2024-10-07T13:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/biomea-fusion-to-present-at-the-1st-annual-asian-conference-globenewswire 2024-10-07T13:06:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomea-fusion-to-present-at-the-1st-annual-asian-conference-globenewswire 2024-10-07T13:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/anixa-biosciences-appoints-suyasha-gupta-as-senior-director-of-clinical-development 2024-10-07T12:54:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anixa-biosciences-appoints-suyasha-gupta-as-senior-director-of-clinical-development 2024-10-07T12:54:54+00:00 weekly 0.7 https://trial.medpath.com/news/fluoguide-submits-clinical-trial-application-for-head-and-neck-cancer-treatment 2024-10-07T12:43:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fluoguide-submits-clinical-trial-application-for-head-and-neck-cancer-treatment 2024-10-07T12:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/rege-nephro-co-ltd-successfully-completes-series-b-funding-to-accelerate-kidney 2024-10-07T12:36:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rege-nephro-co-ltd-successfully-completes-series-b-funding-to-accelerate-kidney 2024-10-07T12:36:14+00:00 weekly 0.7 https://trial.medpath.com/news/trinity-biotech-announces-positive-pre-pivotal-trial-results-for-its-next-generation 2024-10-07T12:34:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trinity-biotech-announces-positive-pre-pivotal-trial-results-for-its-next-generation 2024-10-07T12:34:49+00:00 weekly 0.7 https://trial.medpath.com/news/design-and-rationale-for-an-empirical-investigation-of-the-resource-use-and-costs-of-trials-journal 2024-10-07T12:25:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/design-and-rationale-for-an-empirical-investigation-of-the-resource-use-and-costs-of-trials-journal 2024-10-07T12:25:48+00:00 weekly 0.7 https://trial.medpath.com/news/bias-found-when-drug-manufacturers-fund-clinical-trials-ohio-state-news 2024-10-07T12:16:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bias-found-when-drug-manufacturers-fund-clinical-trials-ohio-state-news 2024-10-07T12:16:31+00:00 weekly 0.7 https://trial.medpath.com/news/bioatla-to-score-up-to-133m-san-diego-business-journal 2024-10-07T12:12:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioatla-to-score-up-to-133m-san-diego-business-journal 2024-10-07T12:12:41+00:00 weekly 0.7 https://trial.medpath.com/news/monopar-initiates-clinical-trial-of-novel-upar-targeted-globenewswire 2024-10-07T12:09:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/monopar-initiates-clinical-trial-of-novel-upar-targeted-globenewswire 2024-10-07T12:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/phio-announces-data-showcasing-intasyl-s-role-in-helping-immune-cells-target-and-kill 2024-10-07T12:05:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phio-announces-data-showcasing-intasyl-s-role-in-helping-immune-cells-target-and-kill 2024-10-07T12:05:57+00:00 weekly 0.7 https://trial.medpath.com/news/halia-therapeutics-announces-first-healthy-volunteer-dosed-with-ht-4253-a-novel-oral 2024-10-07T12:04:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/halia-therapeutics-announces-first-healthy-volunteer-dosed-with-ht-4253-a-novel-oral 2024-10-07T12:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/bionomics-issues-shareholder-letter-highlighting-recent-achievements-and-strategic-vision 2024-10-07T12:02:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bionomics-issues-shareholder-letter-highlighting-recent-achievements-and-strategic-vision 2024-10-07T12:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/cytomed-therapeutics-first-in-human-phase-i-angelica-clinical-trial-using-its-patented-donor 2024-10-07T12:00:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytomed-therapeutics-first-in-human-phase-i-angelica-clinical-trial-using-its-patented-donor 2024-10-07T12:00:10+00:00 weekly 0.7 https://trial.medpath.com/news/brainstorm-cell-therapeutics-to-provide-corporate-update-on-phase-3b-nurown-r-trial-at 2024-10-07T11:52:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brainstorm-cell-therapeutics-to-provide-corporate-update-on-phase-3b-nurown-r-trial-at 2024-10-07T11:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/prescription-digital-therapeutics-addressing-unmet-needs-among-patients-with-mental 2024-10-07T11:47:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prescription-digital-therapeutics-addressing-unmet-needs-among-patients-with-mental 2024-10-07T11:47:19+00:00 weekly 0.7 https://trial.medpath.com/news/advancements-in-early-detection-and-innovative-therapies-targeting-tau-pathology 2024-10-07T11:46:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancements-in-early-detection-and-innovative-therapies-targeting-tau-pathology 2024-10-07T11:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-therapeutics-announces-initiation-of-haelo-phase-3-study-of-ntla-2002-an-stock-titan 2024-10-07T11:40:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-therapeutics-announces-initiation-of-haelo-phase-3-study-of-ntla-2002-an-stock-titan 2024-10-07T11:40:15+00:00 weekly 0.7 https://trial.medpath.com/news/hybrytetm-expanded-treatment-results-to-be-presented-at-the-european-organisation-for 2024-10-07T11:34:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hybrytetm-expanded-treatment-results-to-be-presented-at-the-european-organisation-for 2024-10-07T11:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/biodesix-announces-new-data-presentation-at-chest-2024-annual-meeting-and-the-biospace 2024-10-07T11:15:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biodesix-announces-new-data-presentation-at-chest-2024-annual-meeting-and-the-biospace 2024-10-07T11:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/virios-therapeutics-inc-and-wex-pharmaceuticals-inc-globenewswire 2024-10-07T11:08:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/virios-therapeutics-inc-and-wex-pharmaceuticals-inc-globenewswire 2024-10-07T11:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/inspiremd-announces-approval-of-investigational-device-exemption-ide-application-for 2024-10-07T11:07:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inspiremd-announces-approval-of-investigational-device-exemption-ide-application-for 2024-10-07T11:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/cytomed-therapeutics-first-in-human-phase-i-angelica-globenewswire 2024-10-07T11:04:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytomed-therapeutics-first-in-human-phase-i-angelica-globenewswire 2024-10-07T11:04:21+00:00 weekly 0.7 https://trial.medpath.com/news/compound-discovered-at-university-of-montana-making-next-steps-in-cancer-trials 2024-10-07T10:37:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/compound-discovered-at-university-of-montana-making-next-steps-in-cancer-trials 2024-10-07T10:37:49+00:00 weekly 0.7 https://trial.medpath.com/news/engineered-microparticles-modulate-arginine-metabolism-to-repolarize-tumor-associated 2024-10-07T10:37:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/engineered-microparticles-modulate-arginine-metabolism-to-repolarize-tumor-associated 2024-10-07T10:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/ferring-bolsters-adstiladrin-production-with-finland-expansion-bioprocess-international 2024-10-07T10:25:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ferring-bolsters-adstiladrin-production-with-finland-expansion-bioprocess-international 2024-10-07T10:25:55+00:00 weekly 0.7 https://trial.medpath.com/news/bright-light-therapy-may-ease-multiple-forms-of-depression 2024-10-07T10:10:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bright-light-therapy-may-ease-multiple-forms-of-depression 2024-10-07T10:10:56+00:00 weekly 0.7 https://trial.medpath.com/news/tumor-fraction-based-prognostic-tool-for-cancer-patients-referred-to-early-phase-clinical-trials 2024-10-07T09:53:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tumor-fraction-based-prognostic-tool-for-cancer-patients-referred-to-early-phase-clinical-trials 2024-10-07T09:53:23+00:00 weekly 0.7 https://trial.medpath.com/news/medinol-announces-first-in-human-implantation-of-drug-eluting-peripheral-stent-in-australia 2024-10-07T09:52:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medinol-announces-first-in-human-implantation-of-drug-eluting-peripheral-stent-in-australia 2024-10-07T09:52:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-warning-letters-september-2024-edition-the-medicine-maker 2024-10-07T09:47:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-warning-letters-september-2024-edition-the-medicine-maker 2024-10-07T09:47:41+00:00 weekly 0.7 https://trial.medpath.com/news/blue-shield-of-california-slashes-humira-biosimilar-price-by-75-through-direct-purchase-model 2024-10-07T09:47:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blue-shield-of-california-slashes-humira-biosimilar-price-by-75-through-direct-purchase-model 2024-10-07T09:47:08+00:00 weekly 0.7 https://trial.medpath.com/news/onkure-and-reneo-pharmaceuticals-complete-merger 2024-10-07T09:01:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/onkure-and-reneo-pharmaceuticals-complete-merger 2024-10-07T09:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/bedaquiline-versus-injectable-containing-regimens-for-rifampicin-resistant-and-multidrug 2024-10-07T08:34:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bedaquiline-versus-injectable-containing-regimens-for-rifampicin-resistant-and-multidrug 2024-10-07T08:34:33+00:00 weekly 0.7 https://trial.medpath.com/news/cd7-car-t-cell-therapy-shows-promise-for-leukaemia-pharmaceutical-technology 2024-10-07T08:25:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cd7-car-t-cell-therapy-shows-promise-for-leukaemia-pharmaceutical-technology 2024-10-07T08:25:48+00:00 weekly 0.7 https://trial.medpath.com/news/hugel-accelerates-global-expansion-of-botulinum-toxin-letybo-businesskorea 2024-10-07T08:16:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hugel-accelerates-global-expansion-of-botulinum-toxin-letybo-businesskorea 2024-10-07T08:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/hansa-biopharma-s-hnsa-5487-achieved-rapid-and-highly-robust-igg-reduction-by-more 2024-10-07T08:12:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hansa-biopharma-s-hnsa-5487-achieved-rapid-and-highly-robust-igg-reduction-by-more 2024-10-07T08:12:36+00:00 weekly 0.7 https://trial.medpath.com/news/wellcome-leap-announces-phase-2-finalists-for-quantum-health-challenge 2024-10-07T08:10:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wellcome-leap-announces-phase-2-finalists-for-quantum-health-challenge 2024-10-07T08:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/news-highlight-crispr-reduces-the-cause-of-blindness-in-monkeys-but-comes-with-toxicity 2024-10-07T08:05:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/news-highlight-crispr-reduces-the-cause-of-blindness-in-monkeys-but-comes-with-toxicity 2024-10-07T08:05:30+00:00 weekly 0.7 https://trial.medpath.com/news/health-canada-approves-label-expansion-for-telix-s-illuccix-r-to-include-patient-selection 2024-10-07T07:58:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-canada-approves-label-expansion-for-telix-s-illuccix-r-to-include-patient-selection 2024-10-07T07:58:51+00:00 weekly 0.7 https://trial.medpath.com/news/will-enanta-pharma-breathe-easy-rttnews 2024-10-07T07:57:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/will-enanta-pharma-breathe-easy-rttnews 2024-10-07T07:57:50+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-s-new-antibiotic-wck-6777-gains-fda-fast-track-status-completes-phase-i-trial 2024-10-07T07:49:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wockhardt-s-new-antibiotic-wck-6777-gains-fda-fast-track-status-completes-phase-i-trial 2024-10-07T07:49:16+00:00 weekly 0.7 https://trial.medpath.com/news/ushering-in-a-new-era-of-fit-for-purpose-clinical-endpoints-for-rett-syndrome 2024-10-07T07:21:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ushering-in-a-new-era-of-fit-for-purpose-clinical-endpoints-for-rett-syndrome 2024-10-07T07:21:58+00:00 weekly 0.7 https://trial.medpath.com/news/pulsesight-therapeutics-to-present-data-on-pst-611-at-ever-congress-2024 2024-10-07T07:06:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pulsesight-therapeutics-to-present-data-on-pst-611-at-ever-congress-2024 2024-10-07T07:06:34+00:00 weekly 0.7